Document:

Exhibit
10.4

 

EXECUTION
COPY

 

SECURITY
AGREEMENT

 

This
SECURITY AGREEMENT, dated as of June 30, 2022 (this “Agreement”), is among Ensysce Biosciences, Inc., a Delaware corporation
(the “Company”), all of the Subsidiaries of the Company (such subsidiaries, the “Guarantors” and
together with the Company, the “Debtors”), the holders of the Company’s Senior Secured Convertible Notes due
eighteen (18) months following their dates of issuance, in the original aggregate principal amount of $8,000,000 (collectively, the “Notes”)
signatory hereto, their endorsees, transferees and assigns (collectively, the “Secured Parties”) and 3i, LP, in its
capacity as agent for the Secured Parties (“Agent”).

 

W
I T N E S S E T H:

 

WHEREAS,
pursuant to the Purchase Agreement (as defined in the Notes), the Secured Parties have severally agreed to extend the loans to the Company
evidenced by the Notes;

 

WHEREAS,
pursuant to a certain Subsidiary Guarantee, dated as of the date hereof (the “Guarantee”), the Guarantors have jointly
and severally agreed to guarantee and act as surety for payment of such Notes; and

 

WHEREAS,
in order to induce the Secured Parties to extend the loans evidenced by the Notes and to purchase the warrants (“Warrants”)
under the Purchase Agreement, each Debtor has agreed to execute and deliver to the Secured Parties this Agreement and to grant the Secured
Parties, pari passu with each other Secured Party and through the Agent (as defined in Section 18 hereof), a security interest
in certain property of such Debtor to secure the prompt payment, performance and discharge in full of all of the Company’s obligations
under the Notes and the Guarantors’ obligations under the Guarantee.

 

NOW,
THEREFORE, in consideration of the agreements herein contained and for other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the parties hereto hereby agree as follows:

 

1.
Certain Definitions. As used in this Agreement, the following terms shall have the meanings set forth in this Section 1. Terms
used but not otherwise defined in this Agreement that are defined in Article 9 of the UCC (such as “account”, “chattel
paper”, “commercial tort claim”, “deposit account”, “document”, “equipment”, “fixtures”,
“general intangibles”, “goods”, “instruments”, “inventory”, “investment property”,
“letter-of-credit rights”, “proceeds” and “supporting obligations”) shall have the respective meanings
given such terms in Article 9 of the UCC.

 

(a)
“Collateral” means the collateral in which the Secured Parties are granted a security interest by this Agreement in
all of Debtors’ assets, and which shall include the following personal property of the Debtors, whether presently owned or existing
or hereafter acquired or coming into existence, wherever situated, and all additions and accessions thereto and all substitutions and
replacements thereof, and all proceeds, products and accounts thereof, including, without limitation, all proceeds from the sale or transfer
of the Collateral and of insurance covering the same and of any tort claims in connection therewith, and all dividends, interest, cash,
notes, securities, equity interest or other property at any time and from time to time acquired, receivable or otherwise distributed
in respect of, or in exchange for, any or all of the Pledged Securities (as defined below):

 

(i)
All goods, including, without limitation, (A) all machinery, equipment, computers, motor vehicles, trucks, tanks, boats, ships, appliances,
furniture, special and general tools, fixtures, test and quality control devices and other equipment of every kind and nature and wherever
situated, together with all documents of title and documents representing the same, all additions and accessions thereto, replacements
therefor, all parts therefor, and all substitutes for any of the foregoing and all other items used and useful in connection with any
Debtor’s businesses and all improvements thereto; and (B) all inventory;

 

    	 

     

    

 

(ii)
All contract rights and other general intangibles, including, without limitation, Intellectual Property, all partnership interests, membership
interests, stock or other securities, rights under any of the Organizational Documents, agreements related to the Pledged Securities,
licenses, distribution and other agreements, computer software (whether “off-the-shelf”, licensed from any third party or
developed by any Debtor), computer software development rights, leases, franchises, customer lists, quality control procedures, grants
and rights, goodwill, Intellectual Property and income tax refunds;

 

(iii)
All accounts, together with all instruments, all documents of title representing any of the foregoing, all rights in any merchandising,
goods, equipment, motor vehicles and trucks which any of the same may represent, and all right, title, security and guaranties with respect
to each account, including any right of stoppage in transit;

 

(iv)
All documents, letter-of-credit rights, instruments and chattel paper;

 

(v)
All commercial tort claims;

 

(vi)
All deposit accounts and all cash (whether or not deposited in such deposit accounts);

 

(vii)
All investment property;

 

(viii)
All supporting obligations; and

 

(ix)
All files, records, books of account, business papers, and computer programs; and

 

(x)
the products and proceeds of all of the foregoing Collateral set forth in clauses (i)-(ix) above.

 

    	 

     

    

 

Without
limiting the generality of the foregoing, the “Collateral” shall include all investment property and general intangibles
respecting ownership and/or other equity interests in each Guarantor, including, without limitation, the shares of capital stock and
the other equity interests listed on Schedule H hereto (as the same may be modified from time to time pursuant to the terms hereof),
and any other shares of capital stock and/or other equity interests of any other direct or indirect subsidiary of any Debtor obtained
in the future, and, in each case, all certificates representing such shares and/or equity interests and, in each case, all rights, options,
warrants, stock, other securities and/or equity interests that may hereafter be received, receivable or distributed in respect of, or
exchanged for, any of the foregoing and all rights arising under or in connection with the Pledged Securities, including, but not limited
to, all dividends, interest and cash.

 

Notwithstanding
the foregoing, nothing herein shall be deemed to constitute an assignment of any asset which, in the event of an assignment, becomes
void by operation of applicable law or the assignment of which is otherwise prohibited by applicable law (in each case to the extent
that such applicable law is not overridden by Sections 9-406, 9-407 and/or 9-408 of the UCC or other similar applicable law); provided,
however, that to the extent permitted by applicable law, this Agreement shall create a valid security interest in such asset and,
to the extent permitted by applicable law, this Agreement shall create a valid security interest in the proceeds of such asset.

 

(b)
“Intellectual Property” means the collective reference to all rights, priorities and privileges relating to intellectual
property, whether arising under United States, multinational or foreign laws or otherwise, including, without limitation, (i) all copyrights
arising under the laws of the United States, any other country or any political subdivision thereof, whether registered or unregistered
and whether published or unpublished, all registrations and recordings thereof, and all applications in connection therewith, including,
without limitation, all registrations, recordings and applications in the United States Copyright Office, (ii) all letters patent of
the United States, any other country or any political subdivision thereof, all reissues and extensions thereof, and all applications
for letters patent of the United States or any other country and all divisions, continuations and continuations-in-part thereof, (iii)
all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade dress, service marks, logos,
domain names and other source or business identifiers, and all goodwill associated therewith, now existing or hereafter adopted or acquired,
all registrations and recordings thereof, and all applications in connection therewith, whether in the United States Patent and Trademark
Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof,
or otherwise, and all common law rights related thereto, (iv) all trade secrets arising under the laws of the United States, any other
country or any political subdivision thereof, (v) all rights to obtain any reissues, renewals or extensions of the foregoing, (vi) all
licenses for any of the foregoing, and (vii) all causes of action for infringement of the foregoing.

 

(c)
“Majority in Interest” means, at any time of determination, the majority in interest (based on then-outstanding principal
amounts of Notes at the time of such determination) of the Secured Parties.

 

    	 

     

    

 

(d)
“Necessary Endorsement” means undated stock powers endorsed in blank or other proper instruments of assignment duly
executed and such other instruments or documents as the Agent (as that term is defined below) may reasonably request.

 

(e)
“Obligations” means all of the liabilities and obligations (primary, secondary, direct, contingent, sole, joint or
several) due or to become due, or that are now or may be hereafter contracted or acquired, or owing to, of any Debtor to the Secured
Parties, including, without limitation, all obligations under this Agreement, the Notes, the Warrants, the Guarantee and any other instruments,
agreements or other documents executed and/or delivered in connection herewith or therewith, in each case, whether now or hereafter existing,
voluntary or involuntary, direct or indirect, absolute or contingent, liquidated or unliquidated, whether or not jointly owed with others,
and whether or not from time to time decreased or extinguished and later increased, created or incurred, and all or any portion of such
obligations or liabilities that are paid, to the extent all or any part of such payment is avoided or recovered directly or indirectly
from any of the Secured Parties as a preference, fraudulent transfer or otherwise as such obligations may be amended, supplemented, converted,
extended or modified from time to time. Without limiting the generality of the foregoing, the term “Obligations” shall include,
without limitation: (i) principal of, and interest on the Notes and the loans extended pursuant thereto; (ii) any and all other fees,
indemnities, costs, obligations and liabilities of the Debtors from time to time under or in connection with this Agreement, the Notes,
the Guarantee and any other instruments, agreements or other documents executed and/or delivered in connection herewith or therewith;
and (iii) all amounts (including but not limited to post-petition interest) in respect of the foregoing that would be payable but for
the fact that the obligations to pay such amounts are unenforceable or not allowable due to the existence of a bankruptcy, reorganization
or similar proceeding involving any Debtor.

 

(f)
“Organizational Documents” means with respect to any Debtor, the documents by which such Debtor was organized (such
as a certificate of incorporation, certificate of limited partnership or articles of organization, and including, without limitation,
any certificates of designation for preferred stock or other forms of preferred equity) and which relate to the internal governance of
such Debtor (such as bylaws, a partnership agreement or an operating, limited liability or members agreement).

 

(g)
“Pledged Interests” shall have the meaning ascribed to such term in Section 4(j).

 

(h)
“Pledged Securities” shall have the meaning ascribed to such term in Section 4(i).

 

(i)
“UCC” means the Uniform Commercial Code of the State of Nevada and or any other applicable law of any state or states
which has jurisdiction with respect to all, or any portion of, the Collateral or this Agreement, from time to time. It is the intent
of the parties that defined terms in the UCC should be construed in their broadest sense so that the term “Collateral” will
be construed in its broadest sense. Accordingly if there are, from time to time, changes to defined terms in the UCC that broaden the
definitions, they are incorporated herein and if existing definitions in the UCC are broader than the amended definitions, the existing
ones shall be controlling.

 

    	 

     

    

 

2.
Grant of Security Interest in Collateral. As an inducement for the Secured Parties to extend the loans as evidenced by the Notes
and to purchase the Warrants and to secure the complete and timely payment, performance and discharge in full, as the case may be, of
all of the Obligations, each Debtor hereby unconditionally and irrevocably pledges, grants and hypothecates to the Secured Parties a
security interest in and to, a lien upon and a right of set-off against all of their respective right, title and interest of whatsoever
kind and nature in and to, the Collateral (a “Security Interest” and, collectively, the “Security Interests”).

 

3.
Delivery of Certain Collateral. Contemporaneously or prior to the execution of this Agreement, each Debtor shall deliver or cause
to be delivered to the Agent (a) any and all certificates and other instruments representing or evidencing the Pledged Securities, and
(b) any and all certificates and other instruments or documents representing any of the other Collateral, in each case, together with
all Necessary Endorsements. The Debtors are, contemporaneously with the execution hereof, delivering to Agent, or have previously delivered
to Agent, a true and correct copy of each Organizational Document governing any of the Pledged Securities.

 

4.
Representations, Warranties, Covenants and Agreements of the Debtors. Except as set forth under the corresponding section of the
disclosure schedules delivered to the Secured Parties concurrently herewith (the “Disclosure Schedules”), which Disclosure
Schedules shall be deemed a part hereof, each Debtor represents and warrants to, and covenants and agrees with, the Secured Parties as
follows:

 

(a)
Each Debtor has the requisite corporate, partnership, limited liability company or other power and authority to enter into this Agreement
and otherwise to carry out its obligations hereunder. The execution, delivery and performance by each Debtor of this Agreement and the
filings contemplated therein have been duly authorized by all necessary action on the part of such Debtor and no further action is required
by such Debtor. This Agreement has been duly executed by each Debtor. This Agreement constitutes the legal, valid and binding obligation
of each Debtor, enforceable against each Debtor in accordance with its terms except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization and similar laws of general application relating to or affecting the rights and remedies of creditors
and by general principles of equity.

 

(b)
The Debtors have no place of business or offices where their respective books of account and records are kept (other than temporarily
at the offices of its attorneys or accountants) or places where Collateral is stored or located, except as set forth on Schedule A
attached hereto. Except as specifically set forth on Schedule A, each Debtor is the record owner of the real property where
such Collateral is located, and there exist no mortgages or other liens on any such real property except for Permitted Liens (as defined
below). Except as disclosed on Schedule A, none of such Collateral is in the possession of any consignee, bailee, warehouseman,
agent or processor.

 

    	 

     

    

 

(c)
Except for liens permitted under the Purchase Agreement and except as set forth on Schedule B attached hereto (collectively, the
“Permitted Liens”), the Debtors are the sole owner of the Collateral (except for non-exclusive licenses granted by
any Debtor in the ordinary course of business), free and clear of any liens, security interests, encumbrances, rights or claims, and
are fully authorized to grant the Security Interests. Except as set forth on Schedule C attached hereto, there is not on file
in any governmental or regulatory authority, agency or recording office an effective financing statement, security agreement, license
or transfer or any notice of any of the foregoing (other than those that will be filed in favor of the Secured Parties pursuant to this
Agreement) covering or affecting any of the Collateral. Except as set forth on Schedule C attached hereto and except pursuant
to this Agreement, as long as this Agreement shall be in effect, the Debtors shall not execute and shall not knowingly permit to be on
file in any such office or agency any other financing statement or other document or instrument (except to the extent filed or recorded
in favor of the Secured Parties pursuant to the terms of this Agreement).

 

(d)
No written claim has been received that any Collateral or any Debtor’s use of any Collateral violates the rights of any third party.
There has been no adverse decision to any Debtor’s claim of ownership rights in or exclusive rights to use the Collateral in any
jurisdiction or to any Debtor’s right to keep and maintain such Collateral in full force and effect, and there is no proceeding
involving said rights pending or, to the best knowledge of any Debtor, threatened before any court, judicial body, administrative or
regulatory agency, arbitrator or other governmental authority.

 

(e)
Each Debtor shall at all times maintain its books of account and records relating to the Collateral at its principal place of business
and its Collateral at the locations set forth on Schedule A attached hereto and may not relocate such books of account and records
or tangible Collateral unless it delivers to the Secured Parties at least 30 days prior to such relocation (i) written notice of such
relocation and the new location thereof (which must be within the United States) and (ii) evidence that appropriate financing statements
under the UCC and other necessary documents have been filed and recorded and other steps have been taken to perfect the Security Interests
to create in favor of the Secured Parties a valid, perfected and continuing perfected first priority lien in the Collateral.

 

(f)
This Agreement creates in favor of the Secured Parties a valid security interest in the Collateral, subject only to Permitted Liens securing
the payment and performance of the Obligations. Upon making the filings described in the immediately following paragraph, all security
interests created hereunder in any Collateral which may be perfected by filing Uniform Commercial Code financing statements shall have
been duly perfected. Except for the filing of the Uniform Commercial Code financing statements referred to in the immediately following
paragraph, the recordation of the Intellectual Property Security Agreement (as defined in Section 4(p) hereof) with respect to copyrights
and copyright applications in the United States Copyright Office referred to in paragraph (m), the execution and delivery of deposit
account control agreements satisfying the requirements of Section 9-104(a)(2) of the UCC with respect to each deposit account of the
Debtors, and the delivery of the certificates and other instruments provided in Section 3, no action is necessary to create, perfect
or protect the security interests created hereunder. Without limiting the generality of the foregoing, except for the filing of said
financing statements, the recordation of said Intellectual Property Security Agreement, and the execution and delivery of said deposit
account control agreements, no consent of any third parties and no authorization, approval or other action by, and no notice to or filing
with, any governmental authority or regulatory body is required for (i) the execution, delivery and performance of this Agreement, (ii)
the creation or perfection of the Security Interests created hereunder in the Collateral or (iii) the enforcement of the rights of the
Agent and the Secured Parties hereunder.

 

    	 

     

    

 

(g)
Each Debtor hereby authorizes the Agent to file one or more financing statements under the UCC, with respect to the Security Interests,
with the proper filing and recording agencies in any jurisdiction deemed proper by it.

 

(h)
The execution, delivery and performance of this Agreement by the Debtors does not (i) violate any of the provisions of any Organizational
Documents of any Debtor or any judgment, decree, order or award of any court, governmental body or arbitrator or any applicable law,
rule or regulation applicable to any Debtor or (ii) conflict with, or constitute a default (or an event that with notice or lapse of
time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation (with
or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing any Debtor’s
debt or otherwise) or other understanding to which any Debtor is a party or by which any property or asset of any Debtor is bound or
affected. If any, all required consents (including, without limitation, from stockholders or creditors of any Debtor) necessary for any
Debtor to enter into and perform its obligations hereunder have been obtained.

 

(i)
The capital stock and other equity interests listed on Schedule H hereto (the “Pledged Securities”) represent
all of the capital stock and other equity interests of the Guarantors, set forth in Schedule H-1, and the capital stock and other
equity interests listed on Schedule H-1 hereto represent all capital stock and other equity interests owned, directly or indirectly,
by the Company. All of the Pledged Securities are validly issued, fully paid and nonassessable, and the Company is the legal and beneficial
owner of the Pledged Securities, free and clear of any lien, security interest or other encumbrance except for the security interests
created by this Agreement and other Permitted Liens.

 

(j)
The ownership and other equity interests in partnerships and limited liability companies (if any) included in the Collateral (the “Pledged
Interests”) by their express terms do not provide that they are securities governed by Article 8 of the UCC and are not held
in a securities account or by any financial intermediary.

 

    	 

     

    

 

(k)
Each Debtor shall at all times maintain the liens and Security Interests provided for hereunder as valid and perfected first priority
liens and security interests in the Collateral in favor of the Secured Parties until this Agreement and the Security Interest hereunder
shall be terminated pursuant to Section 14 hereof. Each Debtor hereby agrees to defend the same against the claims of any and all persons
and entities. Each Debtor shall safeguard and protect all Collateral for the account of the Secured Parties. At the request of the Agent,
each Debtor will sign and deliver to the Agent on behalf of the Secured Parties at any time or from time to time one or more financing
statements pursuant to the UCC in form reasonably satisfactory to the Agent and will pay the cost of filing the same in all public offices
wherever filing is, or is deemed by the Agent to be, necessary or desirable to effect the rights and obligations provided for herein.
Without limiting the generality of the foregoing, each Debtor shall pay all fees, taxes and other amounts necessary to maintain the Collateral
and the Security Interests hereunder, and each Debtor shall obtain and furnish to the Agent from time to time, upon demand, such releases
and/or subordinations of claims and liens which may be required to maintain the priority of the Security Interests hereunder.

 

(l)
No Debtor will transfer, pledge, hypothecate, encumber, license, sell or otherwise dispose of any of the Collateral (except for non-exclusive
licenses granted by a Debtor in its ordinary course of business and sales of inventory by a Debtor in its ordinary course of business)
without the prior written consent of a Majority in Interest.

 

(m)
Each Debtor shall keep and preserve its equipment, inventory and other tangible Collateral in good condition, repair and order and shall
not operate or locate any such Collateral (or cause to be operated or located) in any area excluded from insurance coverage.

 

(n)
Each Debtor shall maintain with financially sound and reputable insurers, insurance with respect to the Collateral, including Collateral
hereafter acquired, against loss or damage of the kinds and in the amounts customarily insured against by entities of established reputation
having similar properties similarly situated and in such amounts as are customarily carried under similar circumstances by other such
entities and otherwise as is prudent for entities engaged in similar businesses but in any event sufficient to cover the full replacement
cost thereof. Each Debtor shall cause each insurance policy issued in connection herewith to provide, and the insurer issuing such policy
to certify to the Agent, that (a) the Agent will be named as lender loss payee and additional insured under each such insurance policy;
(b) if such insurance be proposed to be cancelled or materially changed for any reason whatsoever, such insurer will promptly notify
the Agent and such cancellation or change shall not be effective as to the Agent for at least thirty (30) days after receipt by the Agent
of such notice, unless the effect of such change is to extend or increase coverage under the policy; and (c) the Agent will have the
right (but no obligation) at its election to remedy any default in the payment of premiums within thirty (30) days of notice from the
insurer of such default. If no Event of Default (as defined in the Notes) exists and if the proceeds arising out of any claim or series
of related claims do not exceed $100,000, loss payments in each instance will be applied by the applicable Debtor to the repair and/or
replacement of property with respect to which the loss was incurred to the extent reasonably feasible, and any loss payments or the balance
thereof remaining, to the extent not so applied, shall be payable to the applicable Debtor; provided, however, that payments
received by any Debtor after an Event of Default occurs and is continuing or in excess of $100,000 for any occurrence or series of related
occurrences shall be paid to the Agent on behalf of the Secured Parties and, if received by such Debtor, shall be held in trust for the
Secured Parties and immediately paid over to the Agent unless otherwise directed in writing by the Agent. Copies of such policies or
the related certificates, in each case, naming the Agent as lender loss payee and additional insured shall be delivered to the Agent
at least annually and at the time any new policy of insurance is issued.

 

    	 

     

    

 

(o)
Each Debtor shall, within ten (10) days of obtaining knowledge thereof, advise the Secured Parties promptly, in sufficient detail, of
any material adverse change in the Collateral, and of the occurrence of any event which would have a material adverse effect on the value
of the Collateral or on the Secured Parties’ security interest, through the Agent, therein.

 

(p)
Each Debtor shall promptly execute and deliver to the Agent such further assignments, security agreements, financing statements or other
instruments, documents, certificates and assurances and take such further action as the Agent may from time to time request and may in
its sole discretion deem necessary to perfect, protect or enforce the Secured Parties’ security interest in the Collateral including,
without limitation, if applicable, the execution and delivery of a separate security agreement with respect to each Debtor’s Intellectual
Property (“Intellectual Property Security Agreement”) in which the Secured Parties have been granted a security interest
hereunder, substantially in a form reasonably acceptable to the Agent, which Intellectual Property Security Agreement, other than as
stated therein, shall be subject to all of the terms and conditions hereof.

 

(q)
Each Debtor shall permit the Agent and its representatives and agents to inspect the Collateral during normal business hours and upon
reasonable prior notice, and to make copies of records pertaining to the Collateral as may be reasonably requested by the Agent from
time to time.

 

(r)
Each Debtor shall take all steps reasonably necessary to diligently pursue and seek to preserve, enforce and collect any rights, claims,
causes of action and accounts receivable in respect of the Collateral.

 

(s)
Each Debtor shall promptly notify the Secured Parties in sufficient detail upon becoming aware of any attachment, garnishment, execution
or other legal process levied against any Collateral and of any other information received by such Debtor that may materially affect
the value of the Collateral, the Security Interest or the rights and remedies of the Secured Parties hereunder.

 

(t)
All information heretofore, herein or hereafter supplied to the Secured Parties by or on behalf of any Debtor with respect to the Collateral
is accurate and complete in all material respects as of the date furnished.

 

(u)
The Debtors shall at all times preserve and keep in full force and effect their respective valid existence and good standing and any
rights and franchises material to its business.

 

(v)
No Debtor will change its name, type of organization, jurisdiction of organization, organizational identification number (if it has one),
legal or corporate structure, or identity, or add any new fictitious name unless it provides at least 30 days prior written notice to
the Secured Parties of such change and, at the time of such written notification, such Debtor provides any financing statements or fixture
filings necessary to perfect and continue the perfection of the Security Interests granted and evidenced by this Agreement.

 

    	 

     

    

 

(w)
Except in the ordinary course of business, no Debtor may consign any of its inventory or sell any of its inventory on bill and hold,
sale or return, sale on approval, or other conditional terms of sale without the consent of the Agent which shall not be unreasonably
withheld.

 

(x)
No Debtor may relocate its chief executive office to a new location without providing thirty (30) days prior written notification thereof
to the Secured Parties and so long as, at the time of such written notification, such Debtor provides any financing statements or fixture
filings necessary to perfect and continue the perfection of the Security Interests granted and evidenced by this Agreement.

 

(y)
Each Debtor was organized and remains organized solely under the laws of the state set forth next to such Debtor’s name in Schedule
D attached hereto, which Schedule D sets forth each Debtor’s organizational identification number or, if any Debtor
does not have one, states that one does not exist.

 

(z)
(i) The actual name of each Debtor is the name set forth in Schedule D attached hereto; (ii) no Debtor has any trade names except
as set forth on Schedule E attached hereto; (iii) no Debtor has used any name other than that stated in the preamble hereto or
as set forth on Schedule E for the preceding five years; and (iv) no entity has merged into any Debtor or been acquired by any
Debtor within the past five years except as set forth on Schedule E.

 

(z)
At any time and from time to time that any Collateral consists of instruments, certificated securities or other items that require or
permit possession by the secured party to perfect the security interest created hereby, the applicable Debtor shall deliver such Collateral
to the Agent.

 

(aa)
Each Debtor, in its capacity as issuer, hereby agrees to comply with any and all orders and instructions of Agent regarding the Pledged
Interests consistent with the terms of this Agreement without the further consent of any Debtor as contemplated by Section 8-106 (or
any successor section) of the UCC. Further, each Debtor agrees that it shall not enter into a similar agreement (or one that would confer
“control” within the meaning of Article 8 of the UCC) with any other person or entity.

 

(bb)
Each Debtor shall cause all tangible chattel paper constituting Collateral to be delivered to the Agent, or, if such delivery is not
possible, then to cause such tangible chattel paper to contain a legend noting that it is subject to the security interest created by
this Agreement. To the extent that any Collateral consists of electronic chattel paper, the applicable Debtor shall cause the underlying
chattel paper to be “marked” within the meaning of Section 9-105 of the UCC (or successor section thereto).

 

    	 

     

    

 

(cc)
If there is any investment property or deposit account included as Collateral that can be perfected by “control” through
an account control agreement, the applicable Debtor shall cause such an account control agreement, in form and substance in each case
satisfactory to the Agent, to be entered into and delivered to the Agent for the benefit of the Secured Parties.

 

(dd)
To the extent that any Collateral consists of letter-of-credit rights, the applicable Debtor shall cause the issuer of each underlying
letter of credit to consent to an assignment of the proceeds thereof to the Secured Parties.

 

(ee)
To the extent that any Collateral is in the possession of any third party, the applicable Debtor shall join with the Agent in notifying
such third party of the Secured Parties’ security interest in such Collateral and shall use its best efforts to obtain an acknowledgement
and agreement from such third party with respect to the Collateral, in form and substance reasonably satisfactory to the Agent.

 

(ff)
If any Debtor shall at any time hold or acquire a commercial tort claim, such Debtor shall promptly notify the Secured Parties in a writing
signed by such Debtor of the particulars thereof and grant to the Secured Parties in such writing a security interest therein and in
the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance satisfactory to the Agent.

 

(gg)
Each Debtor shall immediately provide written notice to the Secured Parties of any and all accounts which arise out of contracts with
any governmental authority and, to the extent necessary to perfect or continue the perfected status of the Security Interests in such
accounts and proceeds thereof, shall execute and deliver to the Agent an assignment of claims for such accounts and cooperate with the
Agent in taking any other steps required, in its judgment, under the Federal Assignment of Claims Act or any similar federal, state or
local statute or rule to perfect or continue the perfected status of the Security Interests in such accounts and proceeds thereof.

 

(hh)
Each Debtor shall cause each subsidiary of such Debtor to immediately become a party hereto (an “Additional Debtor”),
by executing and delivering an Additional Debtor Joinder in substantially the form of Annex A attached hereto and comply with
the provisions hereof applicable to the Debtors. Concurrent therewith, the Additional Debtor shall deliver replacement schedules for,
or supplements to all other Schedules to (or referred to in) this Agreement, as applicable, which replacement schedules shall supersede,
or supplements shall modify, the Schedules then in effect. The Additional Debtor shall also deliver such opinions of counsel, authorizing
resolutions, good standing certificates, incumbency certificates, organizational documents, financing statements and other information
and documentation as the Agent may reasonably request. Upon delivery of the foregoing to the Agent, the Additional Debtor shall be and
become a party to this Agreement with the same rights and obligations as the Debtors, for all purposes hereof as fully and to the same
extent as if it were an original signatory hereto and shall be deemed to have made the representations, warranties and covenants set
forth herein as of the date of execution and delivery of such Additional Debtor Joinder, and all references herein to the “Debtors”
shall be deemed to include each Additional Debtor.

 

    	 

     

    

 

(ii)
Each Debtor shall vote the Pledged Securities to comply with the covenants and agreements set forth herein and in the Notes.

 

(jj)
Each Debtor shall register the pledge of the applicable Pledged Securities on the books of such Debtor. Each Debtor shall notify each
issuer of Pledged Securities to register the pledge of the applicable Pledged Securities in the name of the Secured Parties on the books
of such issuer. Further, except with respect to certificated securities delivered to the Agent, the applicable Debtor shall deliver to
Agent an acknowledgement of pledge (which, where appropriate, shall comply with the requirements of the relevant UCC with respect to
perfection by registration) signed by the issuer of the applicable Pledged Securities, which acknowledgement shall confirm that: (a)
it has registered the pledge on its books and records; and (b) at any time directed by Agent during the continuation of an Event of Default,
such issuer will transfer the record ownership of such Pledged Securities into the name of any designee of Agent, will take such steps
as may be necessary to effect the transfer, and will comply with all other instructions of Agent regarding such Pledged Securities without
the further consent of the applicable Debtor.

 

(kk)
In the event that, upon an occurrence of an Event of Default, Agent shall sell all or any of the Pledged Securities to another party
or parties (herein called the “Transferee”) or shall purchase or retain all or any of the Pledged Securities, each
Debtor shall, to the extent applicable: (i) deliver to Agent or the Transferee, as the case may be, the articles of incorporation, bylaws,
minute books, stock certificate books, corporate seals, deeds, leases, indentures, agreements, evidences of indebtedness, books of account,
financial records and all other Organizational Documents and records of the Debtors and their direct and indirect subsidiaries; (ii)
use its best efforts to obtain resignations of the persons then serving as officers and directors of the Debtors and their direct and
indirect subsidiaries, if so requested; and (iii) use its best efforts to obtain any approvals that are required by any governmental
or regulatory body in order to permit the sale of the Pledged Securities to the Transferee or the purchase or retention of the Pledged
Securities by Agent and allow the Transferee or Agent to continue the business of the Debtors and their direct and indirect subsidiaries.

 

(ll)
Without limiting the generality of the other obligations of the Debtors hereunder, each Debtor shall promptly (i) cause to be registered
at the United States Copyright Office all of its material copyrights, (ii) cause the security interest contemplated hereby with respect
to all Intellectual Property registered at the United States Copyright Office or United States Patent and Trademark Office to be duly
recorded at the applicable office, and (iii) give the Agent notice whenever it acquires (whether absolutely or by license) or creates
any additional material Intellectual Property.

 

    	 

     

    

 

(mm)
Each Debtor will from time to time, at the joint and several expense of the Debtors, promptly execute and deliver all such further instruments
and documents, and take all such further action as may be necessary or desirable, or as the Agent may reasonably request, in order to
perfect and protect any security interest granted or purported to be granted hereby or to enable the Secured Parties to exercise and
enforce their rights and remedies hereunder and with respect to any Collateral or to otherwise carry out the purposes of this Agreement.

 

(nn)
Schedule F attached hereto lists all of the patents, patent applications, trademarks, trademark applications, registered copyrights,
and domain names owned by any of the Debtors as of the date hereof. Schedule F lists all material licenses in favor of any Debtor
for the use of any patents, trademarks, copyrights and domain names as of the date hereof. All material patents and trademarks of the
Debtors have been duly recorded at the United States Patent and Trademark Office and all material copyrights of the Debtors have been
duly recorded at the United States Copyright Office.

 

(oo)
None of the account debtors or other persons or entities obligated on any of the Collateral is a governmental authority covered by the
Federal Assignment of Claims Act or any similar federal, state or local statute or rule in respect of such Collateral.

 

(pp)
Until the Obligations shall have been paid and performed in full, the Company covenants that it shall promptly direct any direct or indirect
subsidiary of the Company formed or acquired after the date hereof to enter into a Subsidiary Guarantee in favor of the Secured Party,
in the form of Exhibit F to the Purchase Agreement.

 

5.
Effect of Pledge on Certain Rights. If any of the Collateral subject to this Agreement consists of nonvoting equity or ownership
interests (regardless of class, designation, preference or rights) that may be converted into voting equity or ownership interests upon
the occurrence of certain events (including, without limitation, upon the transfer of all or any of the other stock or assets of the
issuer), it is agreed that the pledge of such equity or ownership interests pursuant to this Agreement or the enforcement of any of Agent’s
rights hereunder shall not be deemed to be the type of event which would trigger such conversion rights notwithstanding any provisions
in the Organizational Documents or agreements to which any Debtor is subject or to which any Debtor is party.

 

6.
Defaults. The following events shall be “Events of Default”:

 

(a)
The occurrence of an Event of Default (as defined in the Notes) under the Notes;

 

(b)
Any representation or warranty of any Debtor in this Agreement shall prove to have been incorrect in any material respect when made;

 

(c)
The failure by any Debtor to observe or perform any of its obligations hereunder for five (5) days after delivery to such Debtor of notice
of such failure by or on behalf of a Secured Party unless such default is capable of cure but cannot be cured within such time frame
and such Debtor is using best efforts to cure same in a timely fashion; or

 

    	 

     

    

 

(d)
If any provision of this Agreement shall at any time for any reason be declared to be null and void, or the validity or enforceability
thereof shall be contested by any Debtor, or a proceeding shall be commenced by any Debtor, or by any governmental authority having jurisdiction
over any Debtor, seeking to establish the invalidity or unenforceability thereof, or any Debtor shall deny that any Debtor has any liability
or obligation purported to be created under this Agreement.

 

7.
Duty To Hold In Trust.

 

(a)
Upon the occurrence of any Event of Default and at any time thereafter, each Debtor shall, upon receipt of any revenue, income, dividend,
interest or other sums subject to the Security Interests, whether payable pursuant to the Notes or otherwise, or of any check, draft,
note, trade acceptance or other instrument evidencing an obligation to pay any such sum, hold the same in trust for the Secured Parties
and shall forthwith endorse and transfer any such sums or instruments, or both, to the Secured Parties, pro-rata in proportion to their
respective then-currently outstanding principal amount of Notes for application to the satisfaction of the Obligations (and if any Note
is not outstanding, pro-rata in proportion to the initial purchases of the remaining Notes).

 

(b)
If any Debtor shall become entitled to receive or shall receive any securities or other property (including, without limitation, shares
of Pledged Securities or instruments representing Pledged Securities acquired after the date hereof, or any options, warrants, rights
or other similar property or certificates representing a dividend, or any distribution in connection with any recapitalization, reclassification
or increase or reduction of capital, or issued in connection with any reorganization of such Debtor or any of its direct or indirect
subsidiaries) in respect of the Pledged Securities (whether as an addition to, in substitution of, or in exchange for, such Pledged Securities
or otherwise), such Debtor agrees to (i) accept the same as the agent of the Secured Parties; (ii) hold the same in trust on behalf of
and for the benefit of the Secured Parties; and (iii) to deliver any and all certificates or instruments evidencing the same to Agent
on or before the close of business on the fifth business day following the receipt thereof by such Debtor, in the exact form received
together with the Necessary Endorsements, to be held by Agent subject to the terms of this Agreement as Collateral.

 

8.
Rights and Remedies Upon Default.

 

(a)
Upon the occurrence of any Event of Default, in each case after the lapse of any notice and cure periods and at any time thereafter,
the Secured Parties, acting through the Agent, shall have the right to exercise all of the remedies conferred hereunder and under the
Notes, and the Secured Parties shall have all the rights and remedies of a secured party under the UCC. Without limitation, the Agent,
for the benefit of the Secured Parties, shall have the following rights and powers:

 

(i)
The Agent shall have the right to take possession of the Collateral and, for that purpose, enter, with the aid and assistance of any
person, any premises where the Collateral, or any part thereof, is or may be placed and remove the same, and each Debtor shall assemble
the Collateral and make it available to the Agent at places which the Agent shall reasonably select, whether at such Debtor’s premises
or elsewhere, and make available to the Agent, without rent, all of such Debtor’s respective premises and facilities for the purpose
of the Agent taking possession of, removing or putting the Collateral in saleable or disposable form.

 

    	 

     

    

 

(ii)
Upon notice to the Debtors by Agent, all rights of each Debtor to exercise the voting and other consensual rights which it would otherwise
be entitled to exercise and all rights of each Debtor to receive the dividends and interest which it would otherwise be authorized to
receive and retain, shall cease. Upon such notice, Agent shall have the right to receive, for the benefit of the Secured Parties, any
interest, cash dividends or other payments on the Collateral and, at the option of Agent, to exercise in such Agent’s discretion
all voting rights pertaining thereto. Without limiting the generality of the foregoing, Agent shall have the right (but not the obligation)
to exercise all rights with respect to the Collateral as it were the sole and absolute owner thereof, including, without limitation,
to vote and/or to exchange, at its sole discretion, any or all of the Collateral in connection with a merger, reorganization, consolidation,
recapitalization or other readjustment concerning or involving the Collateral or any Debtor or any of its direct or indirect subsidiaries.

 

(iii)
Acting in a commercially reasonable manner, the Agent shall have the right to operate the business of each Debtor using the Collateral
and shall have the right to assign, sell, lease or otherwise dispose of and deliver all or any part of the Collateral, at public or private
sale or otherwise, either with or without special conditions or stipulations, for cash or on credit or for future delivery, in such parcel
or parcels and at such time or times and at such place or places, and upon such terms and conditions as the Agent may deem commercially
reasonable, all without (except as shall be required by applicable statute and cannot be waived) advertisement or demand upon or notice
to any Debtor or right of redemption of a Debtor, which are hereby expressly waived. Upon each such sale, lease, assignment or other
transfer of Collateral, the Agent, for the benefit of the Secured Parties, may, unless prohibited by applicable law which cannot be waived,
purchase all or any part of the Collateral being sold, free from and discharged of all trusts, claims, right of redemption and equities
of any Debtor, which are hereby waived and released.

 

(iv)
The Agent shall have the right (but not the obligation) to notify any account debtors and any obligors under instruments or accounts
to make payments directly to the Agent, on behalf of the Secured Parties, and to enforce the Debtors’ rights against such account
debtors and obligors.

 

(v)
The Agent, for the benefit of the Secured Parties, may (but is not obligated to) direct any financial intermediary or any other person
or entity holding any investment property to transfer the same to the Agent, on behalf of the Secured Parties, or its designee.

 

    	 

     

    

 

(vi)
The Agent may (but is not obligated to) transfer any or all Intellectual Property registered in the name of any Debtor at the United
States Patent and Trademark Office and/or Copyright Office into the name of the Secured Parties or any designee or any purchaser of any
Collateral.

 

(b)
The Agent shall comply with any applicable law in connection with a disposition of Collateral and such compliance will not be considered
adversely to affect the commercial reasonableness of any sale of the Collateral. The Agent may sell the Collateral without giving any
warranties and may specifically disclaim such warranties. If the Agent sells any of the Collateral on credit, the Debtors will only be
credited with payments actually made by the purchaser. In addition, each Debtor waives any and all rights that it may have to a judicial
hearing in advance of the enforcement of any of the Agent’s rights and remedies hereunder, including, without limitation, its right
following an Event of Default to take immediate possession of the Collateral and to exercise its rights and remedies with respect thereto.

 

(c)
For the purpose of enabling the Agent to further exercise rights and remedies under this Section 8 or elsewhere provided by agreement
or applicable law, each Debtor hereby grants to the Agent, for the benefit of the Agent and the Secured Parties, an irrevocable, nonexclusive
license (exercisable without payment of royalty or other compensation to such Debtor) to use, license or sublicense following an Event
of Default, any Intellectual Property now owned or hereafter acquired by such Debtor, and wherever the same may be located, and including
in such license access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs
used for the compilation or printout thereof.

 

9.
Applications of Proceeds. The proceeds of any such sale, lease or other disposition of the Collateral hereunder or from payments
made on account of any insurance policy insuring any portion of the Collateral shall be applied first, to the expenses of retaking, holding,
storing, processing and preparing for sale, selling, and the like (including, without limitation, any taxes, fees and other costs incurred
in connection therewith) of the Collateral, to the reasonable attorneys’ fees and expenses incurred by the Agent in enforcing the
Secured Parties’ rights hereunder and in connection with collecting, storing and disposing of the Collateral, and then to satisfaction
of the Obligations pro rata among the Secured Parties (based on then-outstanding principal amounts of Notes at the time of any such determination),
and to the payment of any other amounts required by applicable law, after which the Secured Parties shall pay to the applicable Debtor
any surplus proceeds. If, upon the sale, license or other disposition of the Collateral, the proceeds thereof are insufficient to pay
all amounts to which the Secured Parties are legally entitled, the Debtors will be liable for the deficiency, together with interest
thereon, at the rate of 18% per annum or the lesser amount permitted by applicable law (the “Default Rate”), and the
reasonable fees of any attorneys employed by the Secured Parties to collect such deficiency. To the extent permitted by applicable law,
each Debtor waives all claims, damages and demands against the Secured Parties arising out of the repossession, removal, retention or
sale of the Collateral, unless due solely to the gross negligence or willful misconduct of the Secured Parties as determined by a final
judgment (not subject to further appeal) of a court of competent jurisdiction.

 

    	 

     

    

 

10.
Securities Law Provision. Each Debtor recognizes that Agent may be limited in its ability to effect a sale to the public of all
or part of the Pledged Securities by reason of certain prohibitions in the Securities Act of 1933, as amended, or other federal or state
securities laws (collectively, the “Securities Laws”), and may be compelled to resort to one or more sales to a restricted
group of purchasers who may be required to agree to acquire the Pledged Securities for their own account, for investment and not with
a view to the distribution or resale thereof. Each Debtor agrees that sales so made may be at prices and on terms less favorable than
if the Pledged Securities were sold to the public, and that Agent has no obligation to delay the sale of any Pledged Securities for the
period of time necessary to register the Pledged Securities for sale to the public under the Securities Laws. Each Debtor shall cooperate
with Agent in its attempt to satisfy any requirements under the Securities Laws (including, without limitation, registration thereunder
if requested by Agent) applicable to the sale of the Pledged Securities by Agent.

 

11.
Costs and Expenses. Each Debtor agrees to pay all reasonable out-of-pocket fees, costs and expenses incurred in connection with
any filing required hereunder, including without limitation, any financing statements pursuant to the UCC, continuation statements, partial
releases and/or termination statements related thereto or any expenses of any searches reasonably required by the Agent. The Debtors
shall also pay all other claims and charges which in the reasonable opinion of the Agent is reasonably likely to prejudice, imperil or
otherwise affect the Collateral or the Security Interests therein. The Debtors will also, upon demand, pay to the Agent the amount of
any and all reasonable expenses, including the reasonable fees and expenses of its counsel and of any experts and agents, which the Agent,
for the benefit of the Secured Parties, may incur in connection with the creation, perfection, protection, satisfaction, foreclosure,
collection or enforcement of the Security Interest and the preparation, administration, continuance, amendment or enforcement of this
Agreement and pay to the Agent the amount of any and all reasonable expenses, including the reasonable fees and expenses of its counsel
and of any experts and agents, which the Agent, for the benefit of the Secured Parties, and the Secured Parties may incur in connection
with (i) the enforcement of this Agreement, (ii) the custody or preservation of, or the sale of, collection from, or other realization
upon, any of the Collateral, or (iii) the exercise or enforcement of any of the rights of the Secured Parties under the Notes. Until
so paid, any fees payable hereunder shall be added to the principal amount of the Notes and shall bear interest at the Default Rate.

 

12.
Responsibility for Collateral. The Debtors assume all liabilities and responsibility in connection with all Collateral, and the
Obligations shall in no way be affected or diminished by reason of the loss, destruction, damage or theft of any of the Collateral or
its unavailability for any reason. Without limiting the generality of the foregoing, (a) neither the Agent nor any Secured Party (i)
has any duty (either before or after an Event of Default) to collect any amounts in respect of the Collateral or to preserve any rights
relating to the Collateral, or (ii) has any obligation to clean-up or otherwise prepare the Collateral for sale, and (b) each Debtor
shall remain obligated and liable under each contract or agreement included in the Collateral to be observed or performed by such Debtor
thereunder. Neither the Agent nor any Secured Party shall have any obligation or liability under any such contract or agreement by reason
of or arising out of this Agreement or the receipt by the Agent or any Secured Party of any payment relating to any of the Collateral,
nor shall the Agent or any Secured Party be obligated in any manner to perform any of the obligations of any Debtor under or pursuant
to any such contract or agreement, to make inquiry as to the nature or sufficiency of any payment received by the Agent or any Secured
Party in respect of the Collateral or as to the sufficiency of any performance by any party under any such contract or agreement, to
present or file any claim, to take any action to enforce any performance or to collect the payment of any amounts which may have been
assigned to the Agent or to which the Agent or any Secured Party may be entitled at any time or times.

 

    	 

     

    

 

13.
Security Interests Absolute. All rights of the Secured Parties and all obligations of the Debtors hereunder, shall be absolute
and unconditional, irrespective of: (a) any lack of validity or enforceability of this Agreement, the Notes or any agreement entered
into in connection with the foregoing, or any portion hereof or thereof; (b) any change in the time, manner or place of payment or performance
of, or in any other term of, all or any of the Obligations, or any other amendment or waiver of or any consent to any departure from
the Notes or any other agreement entered into in connection with the foregoing; (c) any exchange, release or nonperfection of any of
the Collateral, or any release or amendment or waiver of or consent to departure from any other collateral for, or any guarantee, or
any other security, for all or any of the Obligations; (d) any action by the Secured Parties to obtain, adjust, settle and cancel in
its sole discretion any insurance claims or matters made or arising in connection with the Collateral; or (e) any other circumstance
which might otherwise constitute any legal or equitable defense available to a Debtor, or a discharge of all or any part of the Security
Interests granted hereby. Until the Obligations shall have been paid and performed in full, the rights of the Secured Parties shall continue
even if the Obligations are barred for any reason, including, without limitation, the running of the statute of limitations or bankruptcy.
Each Debtor expressly waives presentment, protest, notice of protest, demand, notice of nonpayment and demand for performance. In the
event that at any time any transfer of any Collateral or any payment received by the Secured Parties hereunder shall be deemed by final
order of a court of competent jurisdiction to have been a voidable preference or fraudulent conveyance under the bankruptcy or insolvency
laws of the United States, or shall be deemed to be otherwise due to any party other than the Secured Parties, then, in any such event,
each Debtor’s obligations hereunder shall survive cancellation of this Agreement, and shall not be discharged or satisfied by any
prior payment thereof and/or cancellation of this Agreement, but shall remain a valid and binding obligation enforceable in accordance
with the terms and provisions hereof. Each Debtor waives all right to require the Secured Parties to proceed against any other person
or entity or to apply any Collateral which the Secured Parties may hold at any time, or to marshal assets, or to pursue any other remedy.
Each Debtor waives any defense arising by reason of the application of the statute of limitations to any obligation secured hereby.

 

14.
Term of Agreement. This Agreement and the Security Interests shall terminate on the date on which all payments under the Notes
have been indefeasibly paid in full and all other Obligations have been paid or discharged; provided, however, that all indemnities of
the Debtors contained in this Agreement (including, without limitation, Annex B hereto) shall survive and remain operative and in full
force and effect regardless of the termination of this Agreement.

 

    	 

     

    

 

15.
Power of Attorney; Further Assurances.

 

(a)
Each Debtor authorizes the Agent, and does hereby make, constitute and appoint the Agent and its officers, agents, successors or assigns
with full power of substitution, as such Debtor’s true and lawful attorney-in-fact, with power, in the name of the Agent or such
Debtor, to, after the occurrence and during the continuance of an Event of Default but acting in each event in a commercially reasonable
fashion, (i) endorse any note, checks, drafts, money orders or other instruments of payment (including payments payable under or in respect
of any policy of insurance) in respect of the Collateral that may come into possession of the Agent; (ii) to sign and endorse any financing
statement pursuant to the UCC or any invoice, freight or express bill, bill of lading, storage or warehouse receipts, drafts against
debtors, assignments, verifications and notices in connection with accounts, and other documents relating to the Collateral; (iii) to
pay or discharge taxes, liens, security interests or other encumbrances at any time levied or placed on or threatened against the Collateral;
(iv) to demand, collect, receipt for, compromise, settle and sue for monies due in respect of the Collateral; (v) to transfer any Intellectual
Property or provide licenses respecting any Intellectual Property; and (vi) generally, at the option of the Agent, and at the expense
of the Debtors, at any time, or from time to time, to execute and deliver any and all documents and instruments and to do all acts and
things which the Agent deems necessary to protect, preserve and realize upon the Collateral and the Security Interests granted therein
in order to effect the intent of this Agreement and the Notes all as fully and effectually as the Debtors might or could do; and each
Debtor hereby ratifies all that said attorney shall lawfully do or cause to be done by virtue hereof. This power of attorney is coupled
with an interest and shall be irrevocable for the term of this Agreement and thereafter as long as any of the Obligations shall be outstanding.
The designation set forth herein shall be deemed to amend and supersede any inconsistent provision in the Organizational Documents or
other documents or agreements to which any Debtor is subject or to which any Debtor is a party. Without limiting the generality of the
foregoing, after the occurrence and during the continuance of an Event of Default, each Secured Party is specifically authorized to execute
and file any applications for or instruments of transfer and assignment of any patents, trademarks, copyrights or other Intellectual
Property with the United States Patent and Trademark Office and the United States Copyright Office.

 

(b)
On a continuing basis, each Debtor will make, execute, acknowledge, deliver, file and record, as the case may be, with the proper filing
and recording agencies in any jurisdiction, including, without limitation, the jurisdictions indicated on Schedule C attached
hereto, all such instruments, and take all such action as may reasonably be deemed necessary or advisable, or as reasonably requested
by the Agent, to perfect the Security Interests granted hereunder and otherwise to carry out the intent and purposes of this Agreement,
or for assuring and confirming to the Agent the grant or perfection of a perfected security interest in all the Collateral under the
UCC.

 

(c)
Each Debtor hereby irrevocably appoints the Agent as such Debtor’s attorney-in-fact, with full authority in the place and instead
of such Debtor and in the name of such Debtor, from time to time in the Agent’s discretion, to take any action and to execute any
instrument which the Agent may deem necessary or advisable to accomplish the purposes of this Agreement, including the filing, in its
sole discretion, of one or more financing or continuation statements and amendments thereto, relative to any of the Collateral without
the signature of such Debtor where permitted by law, which financing statements may (but need not) describe the Collateral as “all
assets” or “all personal property” or words of like import, and ratifies all such actions taken by the Agent. This
power of attorney is coupled with an interest and shall be irrevocable for the term of this Agreement and thereafter as long as any of
the Obligations shall be outstanding.

 

    	 

     

    

 

16.
Notices. All notices, requests, demands and other communications hereunder shall be subject to the notice provision of the Purchase
Agreement (as such term is defined in the Notes).

 

17.
Other Security. To the extent that the Obligations are now or hereafter secured by property other than the Collateral or by the
guarantee, endorsement or property of any other person, firm, corporation or other entity, then the Agent shall have the right, in its
sole discretion, to pursue, relinquish, subordinate, modify or take any other action with respect thereto, without in any way modifying
or affecting any of the Secured Parties’ rights and remedies hereunder.

 

18.
Appointment of Agent. The Secured Parties hereby appoint Agent to act as their agent for purposes of exercising any and all rights
and remedies of the Secured Parties hereunder. Agent, by its signature below, accepts such appointment. Such appointment shall continue
until revoked in writing by a Majority in Interest, at which time a Majority in Interest shall appoint a new Agent, provided that Agent
may not be removed as Agent unless Agent shall then hold less than $250,000 in principal amount of Notes; provided, further,
that such removal may occur only if each of the other Secured Parties shall then hold not less than an aggregate of $500,000 in principal
amount of Notes. The Agent shall have the rights, responsibilities and immunities set forth in Annex B hereto.

 

19.
Miscellaneous.

 

(a)
No course of dealing between the Debtors and the Secured Parties, nor any failure to exercise, nor any delay in exercising, on the part
of the Secured Parties, any right, power or privilege hereunder or under the Notes shall operate as a waiver thereof; nor shall any single
or partial exercise of any right, power or privilege hereunder or thereunder preclude any other or further exercise thereof or the exercise
of any other right, power or privilege.

 

(b)
All of the rights and remedies of the Secured Parties with respect to the Collateral, whether established hereby or by the Notes or by
any other agreements, instruments or documents or by law shall be cumulative and may be exercised singly or concurrently.

 

(c)
This Agreement, together with the exhibits and schedules hereto, contain the entire understanding of the parties with respect to the
subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the
parties acknowledge have been merged into this Agreement and the exhibits and schedules hereto. No provision of this Agreement may be
waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Debtors, Agent,
and the Secured Parties holding 50.1% or more of the principal amount of Notes then outstanding, or, in the case of a waiver, by the
party against whom enforcement of any such waived provision is sought.

 

    	 

     

    

 

(d)
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.

 

(e)
No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall
any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.

 

(f)
This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company
and the Guarantors may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Secured
Party (other than by merger). Any Secured Party may assign any or all of its rights under this Agreement to any Person (as defined in
the Purchase Agreement) to whom such Secured Party assigns or transfers any Obligations, provided such transferee agrees in writing to
be bound, with respect to the transferred Obligations, by the provisions of this Agreement that apply to the “Secured Parties.”

 

(g)
Each party shall take such further action and execute and deliver such further documents as may be necessary or appropriate in order
to carry out the provisions and purposes of this Agreement.

 

(h)
Except to the extent mandatorily governed by the jurisdiction or situs where the Collateral is located, all questions concerning the
construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance
with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Except to the extent mandatorily
governed by the jurisdiction or situs where the Collateral is located, each Debtor agrees that all proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement and the Notes (whether brought against a party hereto or its
respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the
state and federal courts sitting in Clark County, State of Nevada. Except to the extent mandatorily governed by the jurisdiction or situs
where the Collateral is located, each Debtor hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in Clark County, State of Nevada for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any proceeding, any claim that it
is not personally subject to the jurisdiction of any such court, that such proceeding is improper. Each party hereto hereby irrevocably
waives personal service of process and consents to process being served in any such proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Each party hereto hereby irrevocably
waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of
or relating to this Agreement or the transactions contemplated hereby.

 

    	 

     

    

 

(i)
This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and, all
of which taken together shall constitute one and the same Agreement. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid binding obligation of the party executing (or on whose behalf such signature is executed) the same
with the same force and effect as if such facsimile signature were the original thereof.

 

(j)
All Debtors shall jointly and severally be liable for the obligations of each Debtor to the Secured Parties hereunder.

 

(k)
Each Debtor shall indemnify, reimburse and hold harmless the Agent and the Secured Parties and their respective partners, members, managers,
shareholders, officers, directors, employees and agents (and any other persons with other titles that have similar functions) (collectively,
“Indemnitees”) from and against any and all losses, claims, liabilities, damages, penalties, suits, costs and expenses,
of any kind or nature, (including fees relating to the cost of investigating and defending any of the foregoing) imposed on, incurred
by or asserted against such Indemnitee in any way related to or arising from or alleged to arise from this Agreement or the Collateral,
except any such losses, claims, liabilities, damages, penalties, suits, costs and expenses which result from the gross negligence or
willful misconduct of the Indemnitee as determined by a final, nonappealable decision of a court of competent jurisdiction. This indemnification
provision is in addition to, and not in limitation of, any other indemnification provision in the Notes, the Purchase Agreement (as such
term is defined in the Notes) or any other agreement, instrument or other document executed or delivered in connection herewith or therewith.

 

(l)
Nothing in this Agreement shall be construed to subject Agent or any Secured Party to liability as a partner in any Debtor or any if
its direct or indirect subsidiaries that is a partnership or as a member in any Debtor or any of its direct or indirect subsidiaries
that is a limited liability company, nor shall Agent or any Secured Party be deemed to have assumed any obligations under any partnership
agreement or limited liability company agreement, as applicable, of any such Debtor or any of its direct or indirect subsidiaries or
otherwise, unless and until any such Secured Party exercises its right to be substituted for such Debtor as a partner or member, as applicable,
pursuant hereto.

 

(m)
To the extent that the grant of the security interest in the Collateral and the enforcement of the terms hereof require the consent,
approval or action of any partner or member, as applicable, of any Debtor or any direct or indirect subsidiary of any Debtor or compliance
with any provisions of any of the Organizational Documents, the Debtors hereby grant such consent and approval and waive any such noncompliance
with the terms of said documents.

 

[SIGNATURE
PAGES FOLLOW]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Security Agreement to be duly executed on the day and year first above
written. 1

 

	ENSYSCE
    BIOSCIENCES, INC.	 
	 	 	 
	By:	              	 
	Name: 	 	 
	Title:	 	 
	 	 	 
	EBI
    OpCo, Inc.	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 
	 	 	 
	EBI
    OpERATING, Inc.	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 
	 	 	 
	COVISTAT,
    Inc.	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 

 

[SIGNATURE
PAGE OF AGENT FOLLOWS]

 

    	 

     

    

 

[SIGNATURE
PAGE OF AGENT TO SECURITY AGREEMENT]

 

	3i,
    LP	 
	 	 	 
	By:	 	 
	Name: 	 	 
	Title:	 	 

 

[SIGNATURE
PAGE OF HOLDERS FOLLOWS]

 

    	 

     

    

 

[SIGNATURE
PAGE OF HOLDERS TO SECURITY AGREEMENT]

 

Name
of Investing Entity: __________________________

 

Signature
of Authorized Signatory of Investing entity: _________________________

 

Name
of Authorized Signatory: _________________________

 

Title
of Authorized Signatory: __________________________

 

    	 

     

    

 

ANNEX
A

to

SECURITY

AGREEMENT

 

FORM
OF ADDITIONAL DEBTOR JOINDER

 

Security
Agreement dated as of June [30], 2022 made by

Ensysce Biosciences, Inc., and its subsidiaries party thereto from time to time, as Debtors

to and in favor of the Secured Parties identified therein (the “Security Agreement”)

 

Reference
is made to the Security Agreement as defined above; capitalized terms used herein and not otherwise defined herein shall have the meanings
given to such terms in, or by reference in, the Security Agreement.

 

The
undersigned hereby agrees that upon delivery of this Additional Debtor Joinder to the Secured Parties referred to above, the undersigned
shall (a) be an Additional Debtor under the Security Agreement, (b) have all the rights and obligations of the Debtors under the Security
Agreement as fully and to the same extent as if the undersigned was an original signatory thereto and (c) be deemed to have made the
representations and warranties set forth therein as of the date of execution and delivery of this Additional Debtor Joinder. WITHOUT
LIMITING THE GENERALITY OF THE FOREGOING, THE UNDERSIGNED SPECIFICALLY GRANTS TO THE SECURED PARTIES A SECURITY INTEREST IN THE COLLATERAL
AS MORE FULLY SET FORTH IN THE SECURITY AGREEMENT AND ACKNOWLEDGES AND AGREES TO THE WAIVER OF JURY TRIAL PROVISIONS SET FORTH THEREIN.

 

Attached
hereto are supplemental and/or replacement Schedules to the Security Agreement, as applicable.

 

An
executed copy of this Joinder shall be delivered to the Secured Parties, and the Secured Parties may rely on the matters set forth herein
on or after the date hereof. This Joinder shall not be modified, amended or terminated without the prior written consent of the Secured
Parties.

 

IN
WITNESS WHEREOF, the undersigned has caused this Joinder to be executed in the name and on behalf of the undersigned.

 

	 	Name
    of Additional Debtor
	 	 	 
	 	By:	     
	 	Name:	 
	 	Title:	 
	 	 	 
	 	Address:
	 	 	 
	Dated:

                                                         
	 	 

 

    	 

     

    

 

ANNEX
B

to

SECURITY

AGREEMENT

THE AGENT

 

1.
Appointment. The Secured Parties (all capitalized terms used herein and not otherwise defined shall have the respective meanings
provided in the Security Agreement to which this Annex B is attached (the “Agreement”)), by their acceptance of the
benefits of the Agreement, hereby designate 3i, LP (“Agent”) as the Agent to act as specified herein and in the Agreement.
Each Secured Party shall be deemed irrevocably to authorize the Agent to take such action on its behalf under the provisions of the Agreement
and any other Transaction Document (as such term is defined in the Purchase Agreement) and to exercise such powers and to perform such
duties hereunder and thereunder as are specifically delegated to or required of the Agent by the terms hereof and thereof and such other
powers as are reasonably incidental thereto. The Agent may perform any of its duties hereunder by or through its agents or employees.

 

2.
Nature of Duties. The Agent shall have no duties or responsibilities except those expressly set forth in the Agreement.
Neither the Agent nor any of its partners, members, managers, shareholders, officers, directors, employees or agents shall be liable
for any action taken or omitted by it as such under the Agreement or hereunder or in connection herewith or therewith, be responsible
for the consequence of any oversight or error of judgment or answerable for any loss, unless caused solely by its or their gross negligence
or willful misconduct as determined by a final judgment (not subject to further appeal) of a court of competent jurisdiction. The duties
of the Agent shall be mechanical and administrative in nature; the Agent shall not have by reason of the Agreement or any other Transaction
Document a fiduciary relationship in respect of any Debtor or any Secured Party; and nothing in the Agreement or any other Transaction
Document, expressed or implied, is intended to or shall be so construed as to impose upon the Agent any obligations in respect of the
Agreement or any other Transaction Document except as expressly set forth herein and therein.

 

3.
Lack of Reliance on the Agent. Independently and without reliance upon the Agent, each Secured Party, to the extent it deems appropriate,
has made and shall continue to make (i) its own independent investigation of the financial condition and affairs of the Company and its
subsidiaries in connection with such Secured Party’s investment in the Debtors, the creation and continuance of the Obligations,
the transactions contemplated by the Transaction Documents, and the taking or not taking of any action in connection therewith, and (ii)
its own appraisal of the creditworthiness of the Company and its subsidiaries, and of the value of the Collateral from time to time,
and the Agent shall have no duty or responsibility, either initially or on a continuing basis, to provide any Secured Party with any
credit, market or other information with respect thereto, whether coming into its possession before any Obligations are incurred or at
any time or times thereafter. The Agent shall not be responsible to the Debtors or any Secured Party for any recitals, statements, information,
representations or warranties herein or in any document, certificate or other writing delivered in connection herewith, or for the execution,
effectiveness, genuineness, validity, enforceability, perfection, collectibility, priority or sufficiency of the Agreement or any other
Transaction Document, or for the financial condition of the Debtors or the value of any of the Collateral, or be required to make any
inquiry concerning either the performance or observance of any of the terms, provisions or conditions of the Agreement or any other Transaction
Document, or the financial condition of the Debtors, or the value of any of the Collateral, or the existence or possible existence of
any default or Event of Default under the Agreement, the Notes or any of the other Transaction Documents.

 

    	 

     

    

 

4.
Certain Rights of the Agent. The Agent shall have the right to take any action with respect to the Collateral, on behalf of all
of the Secured Parties. To the extent practical, the Agent shall request instructions from the Secured Parties with respect to any material
act or action (including failure to act) in connection with the Agreement or any other Transaction Document, and shall be entitled to
act or refrain from acting in accordance with the instructions of a Majority in Interest; if such instructions are not provided despite
the Agent’s request therefor, the Agent shall be entitled to refrain from such act or taking such action, and if such action is
taken, shall be entitled to appropriate indemnification from the Secured Parties in respect of actions to be taken by the Agent; and
the Agent shall not incur liability to any person or entity by reason of so refraining. Without limiting the foregoing, (a) no Secured
Party shall have any right of action whatsoever against the Agent as a result of the Agent acting or refraining from acting hereunder
in accordance with the terms of the Agreement or any other Transaction Document, and the Debtors shall have no right to question or challenge
the authority of, or the instructions given to, the Agent pursuant to the foregoing and (b) the Agent shall not be required to take any
action which the Agent believes (i) could reasonably be expected to expose it to personal liability or (ii) is contrary to this Agreement,
the Transaction Documents or applicable law.

 

5.
Reliance. The Agent shall be entitled to rely, and shall be fully protected in relying, upon any writing, resolution, notice,
statement, certificate, telex, teletype or telecopier message, cablegram, radiogram, order or other document or telephone message signed,
sent or made by the proper person or entity, and, with respect to all legal matters pertaining to the Agreement and the other Transaction
Documents and its duties thereunder, upon advice of counsel selected by it and upon all other matters pertaining to this Agreement and
the other Transaction Documents and its duties thereunder, upon advice of other experts selected by it. Anything to the contrary notwithstanding,
the Agent shall have no obligation whatsoever to any Secured Party to assure that the Collateral exists or is owned by the Debtors or
is cared for, protected or insured or that the liens granted pursuant to the Agreement have been properly or sufficiently or lawfully
created, perfected, or enforced or are entitled to any particular priority.

 

6.
Indemnification. To the extent that the Agent is not reimbursed and indemnified by the Debtors, the Secured Parties will
jointly and severally reimburse and indemnify the Agent, in proportion to their initially purchased respective principal amounts of Notes,
from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements
of any kind or nature whatsoever which may be imposed on, incurred by or asserted against the Agent in performing its duties hereunder
or under the Agreement or any other Transaction Document, or in any way relating to or arising out of the Agreement or any other Transaction
Document except for those determined by a final judgment (not subject to further appeal) of a court of competent jurisdiction to have
resulted solely from the Agent’s own gross negligence or willful misconduct. Prior to taking any action hereunder as Agent, the
Agent may require each Secured Party to deposit with it sufficient sums as it determines in good faith is necessary to protect the Agent
for costs and expenses associated with taking such action.

 

    	 

     

    

 

7.
Resignation by the Agent.

 

(a)
The Agent may resign from the performance of all its functions and duties under the Agreement and the other Transaction Documents at
any time by giving thirty (30) days’ prior written notice (as provided in the Agreement) to the Debtors and the Secured Parties.
Such resignation shall take effect upon the appointment of a successor Agent pursuant to clauses (b) and (c) below.

 

(b)
Upon any such notice of resignation, the Secured Parties, acting by a Majority in Interest, shall appoint a successor Agent hereunder.

 

(c)
If a successor Agent shall not have been so appointed within said 30-day period, the Agent shall then appoint a successor Agent who shall
serve as Agent until such time, if any, as the Secured Parties appoint a successor Agent as provided above. If a successor Agent has
not been appointed within such 30-day period, the Agent may petition any court of competent jurisdiction or may interplead the Debtors
and the Secured Parties in a proceeding for the appointment of a successor Agent, and all fees, including, but not limited to, extraordinary
fees associated with the filing of interpleader and expenses associated therewith, shall be payable by the Debtors on demand.

 

8.
Rights with respect to Collateral. Each Secured Party agrees with all other Secured Parties and the Agent (i) that it shall
not, and shall not attempt to, exercise any rights with respect to its security interest in the Collateral, whether pursuant to any other
agreement or otherwise (other than pursuant to this Agreement), or take or institute any action against the Agent or any of the other
Secured Parties in respect of the Collateral or its rights hereunder (other than any such action arising from the breach of this Agreement)
and (ii) that such Secured Party has no other rights with respect to the Collateral other than as set forth in this Agreement and the
other Transaction Documents. Upon the acceptance of any appointment as Agent hereunder by a successor Agent, such successor Agent shall
thereupon succeed to and become vested with all the rights, powers, privileges and duties of the retiring Agent and the retiring Agent
shall be discharged from its duties and obligations under the Agreement. After any retiring Agent’s resignation or removal hereunder
as Agent, the provisions of the Agreement including this Annex B shall inure to its benefit as to any actions taken or omitted to be
taken by it while it was Agent.

 

    	 

     

    

 

Schedule
A

 

(a)
The following are all other locations in the United States of America or any other location in which the Company maintains any books
or records relating to any of the Collateral consisting of accounts, instruments, chattel paper, general intangibles or mobile goods:

 

	Address	 	County	 	State/Country
	 	 	 	 	 

 

Source:
UCC §9-301(2) and (3).

 

(b)
The following are all other places of business of the Company in the United States of America or any other location:

 

	Address	 	County	 	State/Country
	 	 	 	 	 

 

Source:
UCC §9-301(2) and (3).

 

(c)
The following are all other locations in the United States of America or any other location where any of the Collateral consisting of
inventory or equipment is located:

 

	Address	 	County	 	State/Country
	 	 	 	 	 

 

Source:
UCC §§-301(2) and (3).

 

(d)
The following are the names and addresses of all persons or entities other than the Company, such as lessees, consignees, warehousemen
or purchasers of chattel paper, which have possession or are intended to have possession of any of the Collateral consisting of instruments,
chattel paper, inventory or equipment:

 

	Name	 	Mailing
    Address	 	County	 	State/Country
	 	 	 	 	 	 	 

 

Source:
UCC §§9-301(2) and (3), 9-312 and 9-313.

 

(c)
The following is a complete list of all bank accounts (including securities and commodities accounts) maintained by the Company
(provide name and address of depository bank, type of account and account number):

 

	Depository
    Bank	 	Bank
    Address	 	Type
    of Account	 	Acct.
    No.
	 	 	 	 	 	 	 

 

    	 

     

    

 

Schedule
B

 

Permitted
Liens

 

    	 

     

    

 

Schedule
C

 

UCC
filing Jurisdictions

 

    	 

     

    

 

Schedule
D

 

	Name	 	Jurisdiction	 	 Organizational identification number
	 	 	 	 	 

 

    	 

     

    

 

Schedule
E

 

Other
Names

 

    	 

     

    

 

Schedule
F

 

Patents
and Trademarks

 

    	 

     

    

 

Schedule
G

 

    	 

     

    

 

Schedule
H

 

Equity
Interests of Guarantors

 

Schedule
H-1

 

Pledged
Securities:

 

	

    

    

    Issuer
		

    

    Record

    Owner
		

    

    Class
    of

    Shares
    
		Percentage
    OwnershipExhibit
10.5

 

EXECUTION
COPY

 

PATENT
SECURITY AGREEMENT 

 

This
PATENT SECURITY AGREEMENT (this “Patent Security Agreement”) is entered into as of June 30, 2022 by and among, Ensysce
Biosciences, Inc., a Delaware corporation (the “Company”), all of the Subsidiaries of the Company (such subsidiaries,
the “Guarantors” and together with the Company, the “Debtors”), the holders of the Company’s
Senior Secured Convertible Notes due eighteen (18) months following their dates of issuance, in the original aggregate principal amount
of $8,000,000 (collectively, the “Notes”) signatory to the Security Agreement (as herein defined), their endorsees,
transferees and assigns (collectively, the “Secured Parties”) and 3i, LP, in its capacity as agent for the Secured
Parties (“Agent”).

 

WHEREAS,
pursuant to the Purchase Agreement (as defined in the Notes), the Secured Parties have severally agreed to extend the loans to the Company
evidenced by the Notes;

 

WHEREAS,
pursuant to a certain Subsidiary Guarantee, dated as of the date hereof (the “Guarantee”), the Guarantors have jointly
and severally agreed to guarantee and act as surety for payment of such Notes;

 

WHEREAS,
in order to induce the Secured Parties to extend the loans evidenced by the Notes and to purchase the warrants (“Warrants”)
under the Securities Purchase Agreement, each Debtor has agreed to execute and deliver to the Secured Parties that certain Security Agreement,
dated as of the date hereof (the “Security Agreement”) and to grant the Secured Parties, pari passu with each
other Secured Party and through the Agent (as defined in Section 18 of the Security Agreement), a security interest in certain property
of such Debtor to secure the prompt payment, performance and discharge in full of all of the Company’s obligations under the Notes
and the Guarantors’ obligations under the Guarantee; and

 

WHEREAS,
in connection with the Security Agreement, the Company the Guarantors have agreed to execute and deliver this Patent Security Agreement
in order to record the security interest granted to the Secured Parties with the United States Patent and Trademark Office;

 

NOW,
THEREFORE, in consideration of the premises and mutual covenants contained herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Company hereby agrees as follows:

 

SECTION
1. Defined Terms. Unless otherwise defined herein, capitalized terms defined in the Security Agreement and used herein have the
meaning given to them in the Security Agreement. The term “Patents” means, collectively, (a) all of the patent and
patent applications, whether United States or foreign, that are owned by the Company, or in which the Company has any right, title or
interest, now or in the future, including but not limited to (i) the patents and patent applications listed on Schedule I hereto (as
the same may be amended pursuant hereto from time to time), (ii) all letters patent of the United States or any other country, and all
applications for letters patent of the United States or any other country; (iii) all re-issues, continuations, divisions, continuations-in-part,
renewals or extensions thereof; (iv) the inventions disclosed or claimed therein, including the right to make, use, practice and/or sell
(or license or otherwise transfer or dispose of) the inventions disclosed or claimed therein; and (v) the right (but not the obligation)
to make and prosecute applications for such patents, (b) all past, present or future rights in, to and associated with the foregoing
throughout the world, whether arising under federal law, state law, common law, foreign law or otherwise, including the following: all
such rights arising out of or associated with the registrations of the foregoing items set forth in clause (a), the right (but not the
obligation) to register claims under any state, federal or foreign patent law or regulation; the right (but not the obligation) to sue
or bring opposition or cancellation proceedings in the name of the Company or the Secured Parties for any and all past, present and future
infringements or dilution of or any other damages or injury to the foregoing or any associated goodwill, and the rights to damages or
profits due or accrued arising out of or in connection with any such past, present or future infringement, dilution, damage or injury;
and (c) any license rights related to the foregoing.

 

    	 

     

    

 

SECTION
2. Grant of Security Interest in Patent Collateral. The Company hereby pledges, collaterally assigns and grants to the Secured
Parties to secure the prompt and complete payment and performance of the Obligations, a security interest (referred to in this Patent
Security Agreement as the “Security Interest”) in all of the Company’s right, title and interest in, to and
under the following, whether now owned or hereafter acquired or arising (collectively, the “Patent Collateral”):

 

	 	(a) all of its Patents and licenses with respect to Patents to which it is a party including those referred to on Schedule I;
	 	 	 
	 	(b) each license with respect to Patents; and
	 	 	 
	 	(c) all products and proceeds (as that term is defined in the UCC) of the foregoing, including any claim by the Company against third parties for past, present or future (i) infringement or dilution of any Patent or any Patents exclusively licensed under any license, including right to receive any damages, or (ii) right to receive license fees, royalties, and other compensation under any license with respect to Patents.

 

SECTION
3. Security for Obligations. This Patent Security Agreement and the Security Interest created hereby secures the payment and performance
of the Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Patent Security
Agreement secures the payment of all amounts which constitute part of the Obligations and would be owed by the Company to the Secured
Parties, whether or not they are unenforceable or not allowable due to the existence of an insolvency proceeding involving the Company.

 

SECTION
4. Security Agreement. The Security Interest granted pursuant to this Patent Security Agreement is granted in conjunction with
the security interests granted to the Secured Parties pursuant to the Security Agreement. The Company hereby acknowledges and affirms
that the rights and remedies of the Secured Parties with respect to the Security Interest in the Patent Collateral made and granted hereby
are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully
set forth herein. To the extent there is any inconsistency between this Patent Security Agreement and the Security Agreement, the Security
Agreement shall control.

 

SECTION
5. Authorization to Supplement. If the Company shall obtain rights to any new Patents, the provisions of this Patent Security
Agreement shall automatically apply thereto. The Company hereby authorizes the Secured Parties unilaterally to modify this Patent Security
Agreement by amending Schedule I to include any such new patent rights of the Company. Notwithstanding the foregoing, no failure
to so modify this Patent Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from the Secured
Parties’ continuing security interest in all Collateral (including the Patent Collateral), whether or not listed on Schedule
I.

 

SECTION
6. Counterparts. This Patent Security Agreement may be executed in any number of counterparts, all of which shall constitute one
and the same instrument, and any party hereto may execute this Patent Security Agreement by signing and delivering one or more counterparts.

 

SECTION
7. Governing Law. This Patent Security Agreement and any claims, controversy, dispute or cause of action (whether in contract
or tort or otherwise) based upon, arising out of or relating to this Patent Security Agreement and the transactions contemplated hereby
shall be governed by, and construed in accordance with, the law of the State of Nevada.

 

[Signature
pages to follow]

 

    	-2-

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Patent Security Agreement to be executed and delivered by its duly authorized offer as of
the date first set forth above.

 

	ENSYSCE
    BIOSCIENCES, INC.	 
	 	 	 
	By:	 	 
	Name:	                  	 
	Title:	 	 
	 	 	 
	EBI
    OpCo, Inc.	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 
	 	 	 
	EBI
    OpERATING, Inc.	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 
	 	 	 
	COVISTAT,
    Inc.	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 

 

[SIGNATURE
PAGE OF AGENT FOLLOWS]

 

    	-3-

     

    

 

[SIGNATURE
PAGE OF AGENT TO SECURITY AGREEMENT]

 

	3i,
    LP	 
	 	 	 
	By:	   	 
	Name:	 	 
	Title	 	 

 

    	-4-

     

    

 

SCHEDULE
I 

to

PATENT
SECURITY AGREEMENT 

PATENT
REGISTRATIONS AND PATENT APPLICATIONS

 

    	-5-

     

    

 

	Title	 	Country	 	Application
    Status	 	Application
    Number	 	Filing
    Date	 	Patent
    Number	 	Issue
    Date
	SINGLE-WALLED
    CARBON NANOTUBES NONCOVALENTLY COATED WITH siRNA AND METHODS RELATED THERETO	 	US	 	Expired	 	61/162933	 	03/24/2009	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CARBON
    NANOTUBES COMPLEXED WITH MULTIPLE BIOACTIVE AGENTS AND METHODS RELATED THERETO	 	US	 	Expired	 	61/179162	 	05/18/2009	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	SINGLE-WALLED
    CARBON NANOTUBE/BIOACTIVE SUBSTANCE COMPLEXES AND METHODS RELATED THERETO	 	US	 	Abandoned	 	12/731,021	 	03/24/2010	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CARBON
    NANOTUBES COMPLEXED WITH MULTIPLE BIOACTIVE AGENTS AND METHODS RELATED THERETO	 	WO	 	National
    phase	 	PCT/US2010/035304	 	05/18/2010	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CARBON
    NANOTUBES COMPLEXED WITH MULTIPLE BIOACTIVE AGENTS AND METHODS RELATED THERETO	 	CA	 	Abandoned	 	2762524	 	05/18/2010	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	SINGLE-WALLED
    CARBON NANOTUBE/SIRNA COMPLEXES AND METHODS RELATED THERETO	 	US	 	Expired	 	61/360942	 	07/02/2010	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	SINGLE-WALLED
    CARBON NANOTUBE/SIRNA COMPLEXES AND METHODS RELATED THERETO	 	US	 	Issued	 	13/175314	 	07/01/2011	 	8772258	 	07/08/2014
	 	 	 	 	 	 	 	 	 	 	 	 	 
	SINGLE-WALLED
    CARBON NANOTUBE/SIRNA COMPLEXES AND METHODS RELATED THERETO	 	WO	 	National
    Phase	 	PCT/US2011/042832	 	07/01/2011	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	SINGLE-WALLED
    CARBON NANOTUBE/SIRNA COMPLEXES AND METHODS RELATED THERETO	 	CA	 	Abandoned	 	2804760	 	07/01/2011	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	SINGLE-WALLED
    CARBON NANOTUBE/SIRNA COMPLEXES AND METHODS RELATED THERETO	 	EP	 	Abandoned	 	11801506.4	 	07/01/2011	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CARBON
    NANOTUBES COMPLEXED WITH MULTIPLE BIOACTIVE AGENTS AND METHODS RELATED THERETO	 	US	 	Abandoned	 	13/321098	 	01/19/2012	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	SINGLE-WALLED
    CARBON NANOTUBE/BIOACTIVE SUBSTANCE COMPLEXES AND METHODS RELATED THERETO	 	US	 	Abandoned	 	13/568815	 	08/07/2012	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	METHODS
    AND COMPOSITIONS OF SINGLE-WALLED CARBON NANOTUBES FOR TREATING LIVER DISEASE	 	US	 	Expired	 	62/839920	 	04/29/2019	 	 	 	 

 

    	-6-

     

    

 

	METHODS
    FOR TREATING VIRAL INFECTIONS	 	US	 	Expired	 	63/003061	 	03/31/2020	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	METHODS
    FOR TREATING VIRAL INFECTIONS WITH NAFAMOSTAT	 	WO	 	Published	 	PCT/US2021/025146	 	03/31/2021	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF PHENOLS	 	US	 	Abandoned	 	60730602	 	26-Oct-05	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF PHENOLS	 	US	 	Abandoned	 	60799984	 	11-May-06	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF PHENOLS	 	US	 	Abandoned	 	60717987	 	16-Sep-05	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ANESTHETIC
    COMPOUNDS	 	US	 	Abandoned	 	12373717	 	13-Nov-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ANESTHETIC
    COMPOUNDS	 	AU	 	Abandoned	 	2007275200	 	19-Jul-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ANESTHETIC
    COMPOUNDS	 	CA	 	Abandoned	 	2656510	 	19-Jul-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ANESTHETIC
    COMPOUNDS	 	EPO	 	Abandoned	 	078131331	 	19-Jul-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ANESTHETIC
    COMPOUNDS	 	JP	 	Abandoned	 	2009521008	 	19-Jul-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ESTER
    LOCAL ANESTHETICS	 	US	 	Expired	 	60832174	 	19-Jul-06	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ESTER
    LOCAL ANESTHETICS	 	US	 	Expired	 	60832694	 	20-Jul-06	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	NOVEL
    ESTER LOCAL ANESTHETICS	 	US	 	Expired	 	60837697	 	14-Aug-06	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ANESTHETIC
    COMPOUNDS	 	WO	 	National
    Phase	 	PCTUS2007073926	 	19-Jul-07	 	 	 	 

 

    	-7-

     

    

 

	ANESTHETIC
    COMPOUNDS	 	US	 	Abandoned	 	12812231	 	10-Nov-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ANESTHETIC
    COMPOUNDS	 	US	 	Expired	 	61022106	 	18-Jan-08	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ANESTHETIC
    COMPOUNDS	 	WO	 	National
    Phase	 	PCTUS2009000223	 	13-Jan-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR TREATING OR PREVENTING PAIN	 	US	 	Abandoned	 	11131778	 	17-May-05	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Expired	 	60572129	 	17-May-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60574262	 	24-May-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60574369	 	24-May-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60574023	 	24-May-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60574049	 	24-May-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60574050	 	24-May-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60574106	 	24-May-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60574135	 	24-May-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60574167	 	24-May-04	 	 	 	 

 

    	-8-

     

    

 

	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60574257	 	24-May-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60574261	 	24-May-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR TREATING OR PREVENTING PAIN	 	WO	 	Closed	 	PCTUS2005017384	 	17-May-05	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF ACTIVE AGENTS	 	US	 	Issued	 	11508042	 	21-Aug-06	 	8163701	 	24-Apr-12
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF ACTIVE AGENTS	 	EPO	 	Abandoned	 	068020593	 	21-Aug-06	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF ACTIVE AGENTS	 	US	 	Closed	 	60711438	 	19-Aug-05	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF ACTIVE AGENTS	 	US	 	Closed	 	60711862	 	25-Aug-05	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF AMPHETAMINES AND OTHER AMINES	 	US	 	Closed	 	60760762	 	20-Jan-06	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF AMPHETAMINES AND OTHER AMINES	 	US	 	Closed	 	60799532	 	10-May-06	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF ACTIVE AGENTS	 	WO	 	National
    Phase	 	PCTUS2006032734	 	21-Aug-06	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	US	 	Issued	 	12302764	 	9-Jun-09	 	8217005	 	10-Jul-12
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	AT	 	Issued	 	077977452	 	24-May-07	 	2046393	 	12-Feb-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	AU	 	Issued	 	2007267510	 	24-May-07	 	2007267510	 	16-May-13

 

    	-9-

     

    

 

	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	AU	 	Issued	 	2013202270	 	24-May-07	 	2013202270	 	7-May-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	BE	 	Issued	 	077977452	 	24-May-07	 	2046393	 	12-Feb-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	BE	 	Issued	 	111725701	 	24-May-07	 	2402037	 	23-Oct-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	BR	 	Issued	 	PI07128193	 	24-May-07	 	PI0712819-3	 	6-Apr-2021
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	CA	 	Issued	 	2653741	 	24-May-07	 	2653741	 	7-Jul-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	CH	 	Issued	 	077977452	 	24-May-07	 	2046393	 	12-Feb-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	CH	 	Issued	 	111725701	 	24-May-07	 	2402037	 	23-Oct-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	CN	 	Issued	 	2007800283954	 	24-May-07	 	ZL200780028395.4	 	26-Feb-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	US	 	Issued	 	13486613	 	1-Jun-12	 	8921418	 	30-Dec-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	US	 	Abandoned	 	14551731	 	24-Nov-14	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	DE	 	Issued	 	077977452	 	24-May-07	 	602007035067.0	 	12-Feb-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	DE	 	Issued	 	111725701	 	24-May-07	 	602007059410.3	 	23-Oct-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	DK	 	Issued	 	077977452	 	24-May-07	 	2046393	 	12-Feb-14

 

    	-10-

     

    

 

	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	EPO	 	Issued	 	077977452	 	24-May-07	 	2046393	 	12-Feb-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	EPO	 	Issued	 	111725701	 	24-May-07	 	2402037	 	23-Oct-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	ES	 	Issued	 	077977452	 	24-May-07	 	2046393	 	12-Feb-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	FI	 	Issued	 	077977452	 	24-May-07	 	2046393	 	12-Feb-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	FR	 	Issued	 	077977452	 	24-May-07	 	2046393	 	12-Feb-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	FR	 	Issued	 	111725701	 	24-May-07	 	2402037	 	23-Oct-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	GB	 	Issued	 	077977452	 	24-May-07	 	2046393	 	12-Feb-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	GB	 	Issued	 	111725701	 	24-May-07	 	2402037	 	23-Oct-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	HK	 	Issued	 	091054683	 	24-May-07	 	HK1127901	 	20-Jun-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	HK	 	Issued	 	121062027	 	24-May-07	 	1165314	 	4-Sep-20
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	IE	 	Issued	 	077977452	 	24-May-07	 	2046393	 	12-Feb-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	IE	 	Issued	 	111725701	 	24-May-07	 	2402037	 	23-Oct-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	IL	 	Issued	 	195360	 	24-May-07	 	195360	 	1-Sep-15

 

    	-11-

     

    

 

	COMPOUNDS
    CAPABLE OF RELEASING PHENOLIC OPIODS THROUGH INTRA-MOLECULAR CYCLIZATION	 	IN	 	Issued	 	4837KOLNP2008	 	24-May-07	 	264370	 	24-Dec-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	IT	 	Issued	 	077977452	 	24-May-07	 	502014902257237	 	12-Feb-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	JP	 	Issued	 	2009512310	 	24-May-07	 	5371746	 	27-Sep-13
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	JP	 	Abandoned	 	2013160111	 	24-May-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	JP	 	Abandoned	 	201522888	 	24-May-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	KR	 	Abandoned	 	1020087031374	 	24-May-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	MX	 	Issued	 	MXa2008014794	 	24-May-07	 	305604	 	28-Nov-12
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	NL	 	Issued	 	077977452	 	24-May-07	 	2046393	 	12-Feb-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	NL	 	Issued	 	111725701	 	24-May-07	 	2402037	 	23-Oct-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	NZ	 	Abandoned	 	573642	 	24-May-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	NZ	 	Abandoned	 	597096	 	24-May-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF PHENOLS, THIOLS AND ANILINES	 	US	 	Expired	 	60809082	 	26-May-06	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	RU	 	Issued	 	2008151690	 	24-May-07	 	2469038	 	10-Dec-12

 

    	-12-

     

    

 

	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	SE	 	Issued	 	077977452	 	24-May-07	 	2046393	 	12-Feb-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	SG	 	Abandoned	 	2008085078	 	24-May-07	 	147830	 	30-Jun-11
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	SG	 	Abandoned	 	2011037835	 	24-May-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	WO	 	National
    Phase	 	PCTUS2007069683	 	24-May-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	ZA	 	Abandoned	 	200810476	 	24-May-07	 	2008/10476	 	25-Aug-10
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF PHENOLIC OPIOIDS	 	ZA	 	Abandoned	 	201004128	 	24-May-07	 	2010/04128	 	30-May-12
	 	 	 	 	 	 	 	 	 	 	 	 	 
	N-17-ALKYLATED
    PRODRUGS OF OPIOIDS	 	US	 	Abandoned	 	12524523	 	16-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF PHENOLS, THIOLS AND ANILINES	 	US	 	Expired	 	60901795	 	16-Feb-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF OPIOIDS	 	US	 	Expired	 	60990193	 	26-Nov-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	N-17-ALKYLATED
    PRODRUGS OF OPIOIDS	 	WO	 	National
    Phase	 	PCTUS2008054144	 	15-Feb-08	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CONTROLLED
    RELEASE OF HYDROMPORPHONE	 	US	 	Expired	 	60990178	 	26-Nov-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRO-DRUGS
    FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS	 	US	 	Issued	 	12324383	 	26-Nov-08	 	9023860	 	5-May-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRO-DRUGS
    FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS	 	US	 	Expired	 	60990184	 	26-Nov-07	 	 	 	 

 

    	-13-

     

    

 

	PRO-DRUGS
    FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS	 	US	 	Expired	 	60992581	 	5-Dec-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	US	 	Issued	 	13121335	 	9-Jun-11	 	8802681	 	12-Aug-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	AU	 	Issued	 	2009305563	 	16-Oct-09	 	2009305563	 	27-Aug-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	BE	 	Issued	 	097405971	 	16-Oct-09	 	2349241	 	19-Jun-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	BR	 	Published	 	PI09197117	 	16-Oct-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	CA	 	Issued	 	2739936	 	16-Oct-09	 	2739936	 	12-Dec-17
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	CH	 	Issued	 	097405971	 	16-Oct-09	 	2349241	 	19-Jun-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	CN	 	Issued	 	2009801415470	 	16-Oct-09	 	ZL200980141547.0	 	4-Jun-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	US	 	Issued	 	14320351	 	30-Jun-14	 	9534014	 	3-Jan-17
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	DE	 	Issued	 	097405971	 	16-Oct-09	 	602009058798.6	 	19-Jun-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	EPO	 	Issued	 	097405971	 	16-Oct-09	 	2349241	 	19-Jun-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	FR	 	Issued	 	097405971	 	16-Oct-09	 	2349241	 	19-Jun-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	GB	 	Issued	 	097405971	 	16-Oct-09	 	2349241	 	19-Jun-19

 

    	-14-

     

    

 

	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	HK	 	Issued	 	121008827	 	16-Oct-09	 	HK1160394	 	17-Jul-20
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	IE	 	Issued	 	097405971	 	16-Oct-09	 	2349241	 	19-Jun-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	IL	 	Issued	 	212081	 	16-Oct-09	 	212081	 	1-Sep-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	IN	 	Issued	 	961MUMNP2011	 	16-Oct-09	 	287462	 	18-Sep-17
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	JP	 	Issued	 	2011532298	 	16-Oct-09	 	5706825	 	6-Mar-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	JP	 	Abandoned	 	2015037724	 	16-Oct-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	KR	 	Abandoned	 	1020117011102	 	16-Oct-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	MX	 	Abandoned	 	MXa2011004095	 	16-Oct-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	MY	 	Abandoned	 	PI2011001686	 	16-Oct-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	NL	 	Issued	 	097405971	 	16-Oct-09	 	2349241	 	19-Jun-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	NZ	 	Abandoned	 	592000	 	16-Oct-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	PH	 	Abandoned	 	12011500732	 	16-Oct-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITION	 	US	 	Expired	 	61106400	 	17-Oct-08	 	 	 	 

 

    	-15-

     

    

 

	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	RU	 	Issued	 	2011119643	 	16-Oct-09	 	2562583	 	12-Aug-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	SG	 	Abandoned	 	2011026929	 	16-Oct-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	WO	 	National
    Phase	 	PCTUS2009061068	 	16-Oct-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PHARMACEUTICAL
    COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS	 	ZA	 	Abandoned	 	201102361	 	16-Oct-09	 	2011/02361	 	26-Sep-12
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE PHENOL-MODIFIED OPIOID PRODRUGS AND INHIBITORS THEREOF	 	US	 	Abandoned	 	12764883	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE PHENOL-MODIFIED OPIOID PRODRUGS AND INHIBITORS THEREOF	 	US	 	Abandoned	 	13686710	 	27-Nov-12	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE PHENOL-MODIFIED OPIOID PRODRUGS AND INHIBITORS THEREOF	 	WO	 	Closed	 	PCTUS2010031955	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE HYDROMORPHONE PRODRUG	 	US	 	Expired	 	61326623	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE HYDROMORPHONE PRODRUG	 	US	 	Abandoned	 	13634528	 	20-Dec-12	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE HYDROMORPHONE PRODRUG	 	US	 	Expired	 	61326621	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE HYDROMORPHONE PRODRUG	 	WO	 	National
    Phase	 	PCTUS2010052744	 	14-Oct-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITION
    COMPRISING ENZYME-CLEAVABLE HYDROMORPHONE PRODRUG	 	US	 	Expired	 	61326619	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE HYDROMORPHONE PRODRUG	 	US	 	Expired	 	61326612	 	21-Apr-10	 	 	 	 

 

    	-16-

     

    

 

	COMPOSITIONS
    OF NICOTINIC AGONISTS AND THERAPEUTIC AGENTS AND METHODS FOR TREATING OR PREVENTING DISEASES OR PAIN	 	US	 	Abandoned	 	11181369	 	13-Jul-05	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587349	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587387	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587396	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587397	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587413	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587474	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587475	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587476	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587477	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587369	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587374	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587375	 	13-Jul-04	 	 	 	 

 

    	-17-

     

    

 

	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587376	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587377	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587379	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587382	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    AND METHODS FOR THE TREATMENT OF PAIN	 	US	 	Closed	 	60587386	 	13-Jul-04	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF PERIPHERAL PHENOLIC OPIOID ANTAGONISTS	 	US	 	Abandoned	 	12524544	 	25-Mar-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRO-DRUGS
    OF PERIPHERAL PHENOLIC OPIOID ANTAGONISTS	 	US	 	Expired	 	60990203	 	26-Nov-07	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PRODRUGS
    OF PERIPHERAL PHENOLIC OPIOID ANTAGONISTS	 	WO	 	National
    Phase	 	PCTUS2008054127	 	15-Feb-08	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PERIPHERAL
    PHENOLIC OPIOID ANTAGONIST	 	US	 	Abandoned	 	12743560	 	13-Jul-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PERIPHERAL
    PHENOLIC OPIOID ANTAGONIST	 	US	 	Expired	 	61090148	 	19-Aug-08	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PERIPHERAL
    PHENOLIC OPIOID ANTAGONIST	 	WO	 	National
    Phase	 	PCTUS2008084978	 	26-Nov-08	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PERIPHERAL
    OPIOID ANTAGONIST	 	US	 	Expired	 	61090149	 	19-Aug-08	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	OXYCODONE
    CARBAMATE PRODRUGS	 	US	 	Expired	 	61240614	 	8-Sep-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	OXYCODONE
    CARBAMATE PRODRUGS	 	US	 	Expired	 	61288116	 	18-Dec-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	OXYCODONE
    CARBAMATE PRODRUGS	 	US	 	Expired	 	61240615	 	8-Sep-09	 	 	 	 

 

    	-18-

     

    

 

	OXYCODONE
    CARBAMATE PRODRUGS	 	US	 	Expired	 	61288121	 	18-Dec-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	US	 	Issued	 	13393470	 	14-May-12	 	9493477	 	15-Nov-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	AU	 	Issued	 	2010293028	 	21-Apr-10	 	2010293028	 	2-Apr-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	AU	 	Abandoned	 	2015201341	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	BR	 	 Issued	 	BR1120120051245	 	21-Apr-10	 	BR112012005124-5	 	9-Nov-2021
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	CA	 	Issued	 	2773340	 	21-Apr-10	 	2773340	 	23-Jul-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	CH	 	Issued	 	108157694	 	21-Apr-10	 	2475429	 	29-Jul-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	CLEAVABLE
    KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	CN	 	Issued	 	2010800481586	 	21-Apr-10	 	CN102695545	 	17-Aug-16

 

    	-19-

     

    

 

	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	US	 	Issued	 	15285818	 	5-Oct-16	 	10028945	 	24-Jul-18
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	DE	 	Issued	 	108157694	 	21-Apr-10	 	602010026325.2	 	29-Jul-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	EPO	 	Issued	 	108157694	 	21-Apr-10	 	2475429	 	29-Jul-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	FR	 	Issued	 	108157694	 	21-Apr-10	 	2475429	 	29-Jul-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	GB	 	Issued	 	108157694	 	21-Apr-10	 	2475429	 	29-Jul-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	HK	 	Issued	 	121130640	 	21-Apr-10	 	HK1172283	 	24-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	IE	 	Issued	 	108157694	 	21-Apr-10	 	2475429	 	29-Jul-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	IL	 	Issued	 	218498	 	21-Apr-10	 	218498	 	1-Jul-17
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	IN	 	Issued	 	2340CHENP2012	 	21-Apr-10	 	338800	 	18-Jun-20

 

    	-20-

     

    

 

	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	JP	 	Abandoned	 	2012527871	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	JP	 	Abandoned	 	2015190867	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	JP	 	Issued	 	2018100108	 	21-Apr-10	 	6778234	 	28-Oct-20
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	MX	 	Issued	 	MXa2012002847	 	21-Apr-10	 	348262	 	5-Jun-17
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	MY	 	Abandoned	 	PI2012001012	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	NL	 	Issued	 	108157694	 	21-Apr-10	 	2475429	 	29-Jul-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	NZ	 	Abandoned	 	598714	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	PH	 	Abandoned	 	12012500485	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	OXYCODONE
    AND HYDROCODONE CARBAMATE PRODRUGS	 	US	 	Expired	 	61240611	 	8-Sep-09	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	OXYCODONE
    AND HYDROCODONE CARBAMATE PRODRUGS	 	US	 	Expired	 	61288148	 	18-Dec-09	 	 	 	 

 

    	-21-

     

    

 

	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	RU	 	Issued	 	2012108874	 	21-Apr-10	 	2600736	 	27-Oct-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	SG	 	Abandoned	 	2012016036	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	WO	 	National
    Phase	 	PCTUS2010031956	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF	 	ZA	 	Abandoned	 	201201682	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	US	 	Issued	 	13346062	 	9-Jan-12	 	8569228	 	29-Oct-13
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	AT	 	Issued	 	127345734	 	9-Jan-12	 	2663187	 	1-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	AU	 	Issued	 	2012205733	 	9-Jan-12	 	2012205733	 	21-Jan-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	BE	 	Issued	 	127345734	 	9-Jan-12	 	2663187	 	1-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	BR	 	Issued	 	BR1120130172967	 	9-Jan-12	 	 BR1120130172967	 	17-Feb-21
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	CA	 	Issued	 	2814763	 	9-Jan-12	 	2814763	 	28-May-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	CH	 	Issued	 	127345734	 	9-Jan-12	 	2663187	 	1-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	CN	 	Issued	 	201280003814X	 	9-Jan-12	 	ZL201280003814.X	 	20-Jan-16

 

    	-22-

     

    

 

	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	US	 	Issued	 	14035871	 	24-Sep-13	 	8962547	 	24-Feb-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	US	 	Issued	 	14593855	 	9-Jan-15	 	9499581	 	22-Nov-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	DE	 	Issued	 	127345734	 	9-Jan-12	 	602012019191.0	 	1-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	DK	 	Issued	 	127345734	 	9-Jan-12	 	2663187	 	1-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	EPO	 	Issued	 	127345734	 	9-Jan-12	 	2663187	 	1-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	ES	 	Issued	 	127345734	 	9-Jan-12	 	2584634	 	1-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	FI	 	Issued	 	127345734	 	9-Jan-12	 	2663187	 	1-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	FR	 	Issued	 	127345734	 	9-Jan-12	 	2663187	 	1-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	GB	 	Issued	 	127345734	 	9-Jan-12	 	2663187	 	1-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	HK	 	Issued	 	141027546	 	9-Jan-12	 	HK1189763	 	7-Jul-17
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	IE	 	Issued	 	127345734	 	9-Jan-12	 	2663187	 	1-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	IL	 	Issued	 	225904	 	9-Jan-12	 	225904	 	1-Jul-20
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME CLEAVABLE OXYCODONE PRODRUG	 	IN	 	Issued	 	2158KOLNP2013	 	9-Jan-12	 	313847	 	7-Jun-19

 

    	-23-

     

    

 

	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	IT	 	Issued	 	127345734	 	9-Jan-12	 	502016000088286	 	1-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	JP	 	Issued	 	2013548605	 	9-Jan-12	 	6016810	 	7-Oct-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	NL	 	Issued	 	127345734	 	9-Jan-12	 	2663187	 	1-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	US	 	Expired	 	61431781	 	11-Jan-11	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	RU	 	Issued	 	2013137452	 	9-Jan-12	 	2609412	 	1-Feb-17
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	SE	 	Issued	 	127345734	 	9-Jan-12	 	2663187	 	1-Jun-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	TW	 	Issued	 	101100923	 	10-Jan-12	 	I526209	 	21-Mar-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	WO	 	National
    Phase	 	PCTUS2012020649	 	9-Jan-12	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	US	 	Issued	 	13346281	 	9-Jan-12	 	8497237	 	30-Jul-13
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	US	 	Expired	 	61431783	 	11-Jan-11	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG	 	WO	 	Closed	 	PCTUS2012020648	 	9-Jan-12	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING TRYPSIN-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	US	 	Expired	 	61326606	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING TRYPSIN-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	WO	 	Closed	 	PCTUS2011031845	 	8-Apr-11	 	 	 	 

 

    	-24-

     

    

 

	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	US	 	Abandoned	 	13634524	 	19-Nov-12	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	BE	 	Issued	 	117724377	 	8-Apr-11	 	2560486	 	21-Nov-18
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	CH	 	Issued	 	117724377	 	8-Apr-11	 	2560486	 	21-Nov-18
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	US	 	Allowed	 	16656409	 	17-Oct-19	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	DE	 	Issued	 	117724377	 	8-Apr-11	 	602011054102.1	 	21-Nov-18
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	US	 	Issued	 	15042906	 	12-Feb-16	 	11179355	 	23-Nov-2021
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	DK	 	Issued	 	117724377	 	8-Apr-11	 	2560486	 	21-Nov-18
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	EPO	 	Issued	 	117724377	 	8-Apr-11	 	2560486	 	21-Nov-18
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	ES	 	Issued	 	117724377	 	8-Apr-11	 	2560486	 	21-Nov-18
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	FR	 	Issued	 	117724377	 	8-Apr-11	 	2560486	 	21-Nov-18
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	GB	 	Issued	 	117724377	 	8-Apr-11	 	2560486	 	21-Nov-18

 

    	-25-

     

    

 

	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	IE	 	Issued	 	117724377	 	8-Apr-11	 	2560486	 	21-Nov-18
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	US	 	Expired	 	61326609	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	SE	 	Issued	 	117724377	 	8-Apr-11	 	2560486	 	21-Nov-18
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	WO	 	National
    Phase	 	PCTUS2011031846	 	8-Apr-11	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING TRYPSIN-CLEAVABLE ACETAMINOPHEN PRODRUGS AND INHIBITORS THEREOF	 	US	 	Expired	 	61326614	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE ACETAMINOPHEN PRODRUGS AND INHIBITORS THEREOF	 	US	 	Expired	 	61326610	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE PHENOL-MODIFIED TAPENTADOL PRODRUG	 	US	 	Issued	 	13634530	 	20-Dec-12	 	9238020	 	19-Jan-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE PHENOL-MODIFIED TAPENTADOL PRODRUG	 	US	 	Expired	 	61326618	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE PHENOL-MODIFIED TAPENTADOL PRODRUG	 	WO	 	National
    Phase	 	PCTUS2010052743	 	14-Oct-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	DIVERSION
    RESISTANT DRUG FORMULATIONS	 	US	 	Expired	 	61930875	 	23-Jan-14	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	DIVERSION
    RESISTANT DRUG FORMULATIONS	 	US	 	Expired	 	62107778	 	26-Jan-15	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	US	 	Abandoned	 	12764877	 	21-Apr-10	 	 	 	 

 

    	-26-

     

    

 

	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	AU	 	Abandoned	 	2010351605	 	21-Apr-10	 	2010351605	 	30-Jul-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	BR	 	Abandoned	 	BR1120120267680	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	CA	 	Abandoned	 	2795222	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	CN	 	Abandoned	 	2010800671025	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	US	 	Issued	 	13686725	 	27-Nov-12	 	9040032	 	26-May-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	US	 	Issued	 	14692526	 	21-Apr-15	 	9585963	 	7-Mar-17
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	EPO	 	Abandoned	 	108503715	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	HK	 	Abandoned	 	131083469	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	IL	 	Abandoned	 	222354	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	IN	 	Abandoned	 	8924DELNP2012	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	JP	 	Abandoned	 	2013506120	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	JP	 	Abandoned	 	2015127573	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	RU	 	Abandoned	 	2012149438	 	21-Apr-10	 	 	 	 

 

    	-27-

     

    

 

	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF	 	WO	 	National
    Phase	 	PCTUS2010031953	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF	 	US	 	Abandoned	 	12764879	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF	 	US	 	Abandoned	 	13708486	 	7-Dec-12	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF	 	US	 	Abandoned	 	108503723	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF	 	WO	 	National
    Phase	 	PCTUS2010031954	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PERIPHERAL
    OPIOID AGONISTS AND PERIPHERAL OPIOID ANTAGONISTS	 	US	 	Abandoned	 	13634532	 	16-Nov-12	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PERIPHERAL
    OPIOID AGONISTS AND PERIPHERAL OPIOID ANTAGONISTS	 	EPO	 	Abandoned	 	117724351	 	8-Apr-11	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PERIPHERAL
    OPIOID AGONISTS AND PERIPHERAL OPIOID ANTAGONISTS	 	US	 	Expired	 	61326617	 	21-Apr-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PERIPHERAL
    OPIOID AGONISTS AND PERIPHERAL OPIOID ANTAGONISTS	 	WO	 	National
    Phase	 	PCTUS2011031844	 	8-Apr-11	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	PERIPHERAL
    OPIOID AGONISTS AND PERIPHERAL OPIOID ANTAGONISTS	 	US	 	Expired	 	61367270	 	23-Jul-10	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	OPIOID
    PRODRUGS WITH HETEROCYCLIC LINKERS	 	US	 	Issued	 	13415790	 	8-Mar-12	 	8685916	 	1-Apr-14
	 	 	 	 	 	 	 	 	 	 	 	 	 
	OPIOID
    PRODRUGS WITH HETEROCYCLIC LINKERS	 	US	 	Abandoned	 	14748015	 	23-Jun-15	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	OPIOID
    PRODRUGS WITH HETEROCYCLIC LINKERS	 	US	 	Issued	 	14166719	 	28-Jan-14	 	9095627	 	4-Aug-15

 

    	-28-

     

    

 

	OPIOID
    PRODRUGS WITH HETEROCYCLIC LINKERS	 	US	 	Expired	 	61451010	 	9-Mar-11	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	OPIOID
    PRODRUGS WITH HETEROCYCLIC LINKERS	 	US	 	Expired	 	61583516	 	5-Jan-12	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	OPIOID
    PRODRUGS WITH HETEROCYCLIC LINKERS	 	WO	 	Closed	 	PCTUS2012028365	 	8-Mar-12	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	US	 	Abandoned	 	13415793	 	8-Mar-12	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	AU	 	Issued	 	2012225337	 	8-Mar-12	 	2012225337	 	11-Aug-16
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	BR	 	Published	 	BR1120130229462	 	8-Mar-12	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	CA	 	Issued	 	2827662	 	8-Mar-12	 	2827662	 	14-Jul-20
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	CN	 	Issued	 	2012800118708	 	8-Mar-12	 	ZL201280011870.8	 	19-Dec-17
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	BE	 	Issued	 	127543734	 	8-Mar-12	 	2683394	 	6-Jan-21
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	CH	 	Issued	 	127543734	 	8-Mar-12	 	2683394	 	6-Jan-21
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	DE	 	Issued	 	127543734	 	8-Mar-12	 	2683394	 	6-Jan-21
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	EPO	 	Issued	 	127543734	 	8-Mar-12	 	2683394	 	6-Jan-21
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	FR	 	Issued	 	127543734	 	8-Mar-12	 	2683394	 	6-Jan-21

 

    	-29-

     

    

 

	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	GB	 	Issued	 	127543734	 	8-Mar-12	 	2683394	 	6-Jan-21
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	HK	 	Issued	 	141067743	 	8-Mar-12	 	HK1193976	 	9-Sep-2021
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	IL	 	Issued	 	228215	 	8-Mar-12	 	228215	 	1-May-19
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	IN	 	Published	 	1603MUMNP2013	 	8-Mar-12	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	JP	 	Issued	 	2013557882	 	8-Mar-12	 	6148182	 	26-May-17
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	US	 	Expired	 	61451019	 	9-Mar-11	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	US	 	Expired	 	61583523	 	5-Jan-12	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	RU	 	Issued	 	2013144368	 	8-Mar-12	 	2608305	 	17-Jan-17
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	US	 	Issued	 	14000594	 	27-Dec-13	 	9139612	 	22-Sep-15
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	US	 	Abandoned	 	14825880	 	13-Aug-15	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVE
    AGENT PRODRUGS WITH HETEROCYCLIC LINKERS	 	WO	 	Closed	 	PCTUS2012028367	 	8-Mar-12	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS	 	US	 	Expired	 	61451041	 	9-Mar-11	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	MODIFIED
    RELEASE COMPOSITIONS OF NAFAMOSTAT AND METHODS OF USING SAME	 	US	 	Expired	 	63158654	 	9-Mar-21	 	 	 	 

 

    	-30-

     

    

 

	MODIFIED
    RELEASE COMPOSITIONS OF NAFAMOSTAT AND METHODS OF USING SAME	 	US	 	Pending	 	17689255	 	8-Mar-22	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	MODIFIED
    RELEASE COMPOSITIONS OF NAFAMOSTAT AND METHODS OF USING SAME	 	WO	 	Pending	 	PCTUS2022019262	 	9-Mar-22	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	MODIFIED
    RELEASE COMPOSITIONS OF NAFAMOSTAT AND METHODS OF USING SAME	 	TW	 	Pending	 	111108587	 	9-Mar-22	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF	 	US	 	Expired	 	63158663	 	9-Mar-21	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF	 	US	 	Pending	 	17689271	 	8-Mar-22	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF	 	WO	 	Pending	 	PCTUS2022019265	 	9-Mar-22	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF	 	TW	 	Pending	 	111108588	 	9-Mar-22	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	US	 	Published	 	17436041	 	2-Sep-21	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	EP	 	Published	 	207673146	 	4-Mar-20	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	US	 	Expired	 	62814630	 	6-Mar-19	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	COMPOSITIONS
    COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF	 	WO	 	National
    Phase	 	PCTUS2020021016	 	10-Sep-20	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	ENZYME-CLEAVABLE
    METHADONE PRODRUGS AND METHODS OF USE THEREOF	 	US	 	Pending	 	63250041	 	29-Sept-21	 	 	 	 

 

    	-31-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]